DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Confidential  Page  1 of 74 TITLE PAG
E 
CLINICAL  STUDY PROTOCOL  
STUDY TITLE:  Phase 3b Multicenter,  Open -Label  Single Arm Study of 
Roxadustat: Either as Conversion from a Continuous 
Erythropoietin Receptor  Activator  (CERA),  or as Initial 
Anemia Treatment in Hemodialysis (HD) Patients - DENALI Study  
PROTOCOL NUMBER:  
FGCL -4592- 097 
SPONSOR:  FibroGen, Inc. 
[ADDRESS_664621]  
San Francisco,  [LOCATION_004]  [ZIP_CODE] [LOCATION_003] 
IND NUMBER:  074454  
STUDY DRUG:  Roxadustat (FG-4592)  
INDICATION:  Anemia  associated  with ESRD  
FIBROGEN  MEDICAL 
MONITOR:  
PROTOCOL  VERS ION 
& DATE:  
ORIGINAL: 
AMENDMENT  1: 
AMENDMENT  2: Name:   
[CONTACT_1641]:  
Telephone:  
Mobile:  
Fax:  
E-mail: 
[ADDRESS_664622] #[STUDY_ID_REMOVED]

DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  2 of 74  
  
 
INVESTIGATOR  SIGNATURE  [CONTACT_513370]  3b Multicenter,  Open -Label  Single  Arm  Study  of Roxadustat: Either as Conversion from 
a Continuous Erythropoietin Receptor Activator (CERA), or as Initial Anemia Treatment in 
Hemodialysis (HD) Patients – DENALI Study  
 
FGCL -4592 -097 
 
Amendment  2, Date:  [ADDRESS_664623] read the protocol, including all appendices  and the current  Investigator’s Brochure (IB),  and I 
agree that it contains all necessary details for me and my staff to conduct this study as described. I 
will conduct this study as outlined herein and will make a reasonable effort to complete the study within the time designated.  
I will provide all study personnel under my supervision copi[INVESTIGATOR_513325], Inc.  I will discuss this material  with them to ensure that they are 
fully informed about the drugs and the study. I will conduct the trial in accordance with the guidelines of Good Clinical Practice (GCP)  including 
the archiving of essential documents, the Declaration of Helsinki, any applicable local health authority, and Institutional Review Board (IRB) requirements. 
 
 
 
  
 
Investigator Name (Printed)  Institution  
 
 
Signature  [CONTACT_513371]:F8E78CBE -578F -461D -BCDA -949A802CD9B4
Roxadustat Protocol FGCL -4592 -097A2
Confidential Page 3of74
CONFIRMATION OF PROTOCOL APPROVAL
Amendment 2, Date: [ADDRESS_664624] 2020 
This protocol is  approved by [CONTACT_2918]. 
09-Sep-20 | 08:22:06 PDT
Date
FibroGen, Inc.
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  4 of 74  
 SUMMARY  OF CHANGES  
Amendment  2 
 
 
Description  of Change   
Rationale for Change  Section(s) 
Affected  
Major  Changes:    
Exclusion criterion # 13 updated From: 
Subject has a diagnosis or suspi[INVESTIGATOR_2798] (e.g., 
complex kidney cyst or Bosniak Category II 
or higher) of renal cell carcinoma as shown 
on renal  imaging  performed  within  24 weeks 
prior to enrollment  
To: 
Subject has a diagnosis or suspi[INVESTIGATOR_2798] (e.g., 
complex  kidney  cyst or Bosniak  Category  II 
or higher) of renal  cell carcinoma (PI’s 
discretion)  To allow  the Principal  Investigator 
[INVESTIGATOR_464436] a determination based on 
clinical judgement in order to 
minimize  additional clinic  visit for 
renal imaging during current pandemic  Synopsis  
Section  5.2 
Minor  editorial  changes  (to correct 
typographical errors and to improve 
consistency and clarity)    
Subjects who wish to permanently 
discontinue roxadustat, after EOT should receive the first ESA dose at least two days  
after the last roxadustat dose instead  of three 
days.  To correct  typographic  error Synopsis 
Section  4.[ADDRESS_664625]  “estimated”  added  before  “Dry  weight 
in HD subjects” for inclusion # 9  For better  clarification  and 
consistency  Synopsis 
Section  5.1 
Exclusion criteria #24 and #[ADDRESS_664626]  “post  
dialysis”  for subject’s dry weight  at 
enrollment  For better  clarification  and 
consistency  Table  S2 
Body  weight  categories  for patents  initiating 
roxadustat dosing have been corrected as 
follows (to align with the synopsis): from ≤ 100 kg to < 100 kg and from > 100 kg to ≥  
[ADDRESS_664627]  an inadvertent  error  Section  7 
Clarified  that central  Hemoglobin  during  
weeks  12 to 24 should  be a part of CBC  For better  clarification  Section  7.3.3  
Protocol requirement to perform renal 
ultrasound  removed  from  screening  visit To align  with the revised 
Exclusion  Criterion  # 13 Table  4 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664628]  of care for CKD or DD-CKD Anemia  ............................................ 23 
2.3. Mechanism  of Action  of Roxadustat  .......................................................................... 24 
2.4. Clinical Experience with Roxadustat  .......................................................................... 26 
2.4.1. Pharmacokinetics  and Pharmacodynamics  ................................................................. 27 
2.5. Summary  .................................................................................................................... 28 
2.6. Roxadustat Dose  Rationale  ......................................................................................... 28 
2.6.1. Maximum Dose  for Roxadustat  .................................................................................. 28  
2.7. Risks/Benefits  of Roxadustat Treatment  .................................................................... 29 
3. OBJECTIVES  AND ENDPOINTS  ............................................................................ 30 
3.1. Objectives  ................................................................................................................... 30 
3.1.1. Primary  Objectives  ..................................................................................................... 30 
3.1.2. Safety/Exploratory Objectives  .................................................................................... 30 
3.2. Efficacy  Endpoints  ..................................................................................................... 30 
3.2.1. Efficacy  Endpoints  ..................................................................................................... 30 
3.2.2. Exploratory Endpoints/Analyses  ................................................................................ 30 
3.3. Safety  Endpoints  ......................................................................................................... 31 
4. STUDY DESIGN  ....................................................................................................... 32 
4.1. Description  of the Study  ............................................................................................. 32 
4.2. Study Rationale  .......................................................................................................... 33 
4.3. Screening  Period  ......................................................................................................... 33 
4.4. Treatment  Period  ........................................................................................................ 33 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664629]- Treatment  Follow- Up Period  .............................................................................. 35 
4.7. Concomitant Medications,  Procedures  and Nondrug Therapi[INVESTIGATOR_014] ................................. 35 
4.7.1. Concomitant Medications  ........................................................................................... 35 
4.7.2. Supplemental Iron Use ............................................................................................... 36 
4.7.3. Rescue Therapy Guidelines  ........................................................................................ 36 
4.7.4. Prohibited Medications/Therapi[INVESTIGATOR_014]/Subst ances  ............................................................ [ADDRESS_664630]  ............................................................................. 43 
6.1. F ormulation  ................................................................................................................ 43 
6.2. Storage  ........................................................................................................................ 43 
6.3. Study Drug  Handling and Disposal  ............................................................................ 43 
6.4. Route of Administration  and Dose  ............................................................................. 43 
6.5. Overdose,  Emergency  Procedures  and Management  of Overdose  ............................. 43 
7. STUDY PROCEDURES  ............................................................................................. 45 
7.1. Study Procedures  by [CONTACT_4838]  / Schedule of Assessments ............................................... 45 
7.2. Screening  Period  ......................................................................................................... 45 
7.2.1. Additional Screening  Assessments  ............................................................................. 46 
7.3. Treatment  Period  ........................................................................................................ 46 
7.3.1.  Day 1 .......................................................................................................................... 46 
7.3.2. Weeks  2 to 8 (Every  2 Weeks,  ±4 days)  ..................................................................... 47 
7.3.3. Weeks  12 to  24 (Every  4 weeks,  ±4 days)  .................................................................. [ADDRESS_664631]- Treatment  Follow- up visit (for subjects discontinuing roxadustat treatment  
at Week  24 or Early  Termination)  (±7 days)  .............................................................. 48 
7.5. Missed  Visits  .............................................................................................................. 48
 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  7 of 74  
 7.6. Unscheduled Visits  ..................................................................................................... 48 
7.7. Laboratory Assessments  ............................................................................................. 49 
7.8. Central  Laboratory  ...................................................................................................... 49 
8. SAFETY  ..................................................................................................................... 51 
8.1. Background  ................................................................................................................. 51 
8.2. Definitions  .................................................................................................................. 51 
8.2.1. Definition  of an Adverse Event  .................................................................................. 51 
8.2.2. Definition  of a Serious Adverse Event  ....................................................................... 51 
8.3. Procedures  for Eliciting,  Recording, and Reporting Adverse Events  ......................... 52 
8.3.1. Adverse Event Reporting Period  ................................................................................ 52 
8.3.2. Adverse Event Eliciting/Reporting  ............................................................................. 52 
8.3.3. Assessing  Adverse Event  Severity  ............................................................................. 53 
8.3.4. Assessing  Relationship  to Study Drug  ....................................................................... 53 
8.3.5. Reporting Serious Adverse Events on the Serious Adverse Event Report Form  ....... 54 
8.3.6. Pregnancies:  Reporting and Follow- up ...................................................................... [ADDRESS_664632]  KEEPI[INVESTIGATOR_1645]  ...................................................... 63 
13.1. Source Documents  ...................................................................................................... 63 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664633]  OF TABLES  
 
Table 1: Conversion from  CERA  to Roxadustat  ........................................................................... 34 
Table 2: Initial Roxadustat Dosing:  ............................................................................................... 34 
Table 3: Recommended  Maximum Daily  Dose  of Statins  ........................................................... 36 
Table 4: Schedule of Assessments  ................................................................................................ 45 
Table 5: Central  Laboratory  Tests  ................................................................................................ [ADDRESS_664634]  OF FIGURES  
 
Figure 1. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF- PHI) Mechanism of 
Action  ......................................................................................................................... 24 
Figure 2: Study Design  Overview  ................................................................................................ [ADDRESS_664635]  OF APPENDICES  
Appendix 1: Roxadustat Dose  Adjustment Rules  ......................................................................... 72 
Appendix 2: Liver  Function Monitoring  ...................................................................................... 73 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664636]  OF ABBREVIATIONS  
 
~ approximately  
Ab antibody  
AE adverse  event  
ALP alkaline  phosphatase  
ALT  alanine  aminotransferase  
AST aspartate  aminotransferase  
AUC  area under  the concentration  curve  
AV arteriovenous  
BIW  twice  weekly  
BL baseline  
BP blood  pressure  
CBC  complete  blood  count  
CFR Code  of Federal  Regulations  
CHr reticulocyte  hemoglobin  content  
CI confidence  interval  
CKD  chronic  kidney  disease  
Cmax maximum  concentration  
CM Concomitant  Medication  
CS clinically  significant  
CYP  cytochrome  P450  
dBP diastolic  blood  pressure  
DD-CKD  dialysis -dependent  chronic  kidney  disease  
EC Ethics  Committee  
ECG  Electrocardiogram  
eCRF  electronic  case report  form 
eEPO  endogenous  erythropoietin  
ELISA  enzyme -linked  immunosorbent  assay  
EOS End of Study  
EOT  End of Treatment  
EPO Erythropoietin  
ESA erythropoiesis -stimulating  agent  
ESRD  end-stage  renal  disease  
ET Early  Termination  (visit)  
FDA  US Food and  Drug  Administration  
GCP  Good  Clinical  Practice  
GGT  gamma -glutamyl  transferase  
Hb Hemoglobin  
HBsAg  hepatitis  B surface  antigen  
hCG human  chorionic  gonadotropin  
HCV  hepatitis  C virus  
HD Hemodialysis  
HEENT  Head  Eye Ear Nose  and Throat  
HIF hypoxia -inducible  factor  
HIF-PH HIF prolyl  hydroxylase  
HIF-PHI HIF prolyl  hydroxylase  inhibitor  
HIPAA  Health  Insurance  Portability  and Accountability  Act 
HIV human  immunodeficiency  virus  
HR heart  rate 
hs-CRP high-sensitivity  C-reactive  protein  
IB Investigator’s  brochure  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664637] 
N (or n) sample  size 
NCS  not clinically  significant  
NDD -CKD  Non-dialysis  dependent  chronic  kidney  disease  
NYHA  New  York  Heart  Association  
PD peritoneal  dialysis  
PH prolyl  hydroxylase  
PK Pharmacokinetics  
QW once  weekly  
RBC  red blood  cell 
RR respi[INVESTIGATOR_513326] -emergent  adverse  event  
TESAE  treatment -emergent  serious  adverse  event  
TIBC  total iron binding  capacity  
TIW three  times  weekly  
TSAT  transferrin  saturation  
UIBC  unsaturated  iron binding  capacity  
ULN  Upper  limit  of normal  
USRDS  United  States  Renal  Data  System  
VEGF  vascular  endothelial  growth  factor  
WBC  white  blood  cell 
Wt Weight  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  11 of 74  
 1. PROTOCOL  SYNOPSIS  
 
 
Study  Title:  Phase  3b Multicenter,  Open -Label  Single  Arm Study  of Roxadustat:  Either 
as Conversion from a Continuous Erythropoietin Receptor Activator 
(CERA), or as Initial Anemia Treatment in Hemodialysis (HD) Patients – 
DENALI  Study  
Protocol 
Number:  FGCL -[ADDRESS_664638]:  Roxadustat  (FG-4592)  
Target 
Population:  Subjects  with end-stage  renal  disease  (ESRD)  on HD, who either  are on a 
stable CERA dose, or are newly initiating anemia treatment  
IND Number:  074454  
Study  Phase:  Phase  3b 
Study  Centers 
Planned:  Approximately  20 sites in the [LOCATION_003]  
Number  of 
Subjects 
Planned:  Approximately  200 subjects  
Primary 
Objective:  To confirm safe and effective Roxadustat dosing regimens among chronic 
dialysis  subjects  converted from  ESA  therapy (>=6  weeks  ESA  treatment)  or 
who are ESA -naïve (<6 weeks ESA treatment)  
Safety / 
Exploratory Objectives:  • Assessment  of treatment -emergent  adverse  events  (TEAEs)  and 
serious adverse events (TESAEs)  
• Laboratory parameters,  including iron indices  
• Utilization  of intravenous (IV) iron 
• Dosing compliance  
• To test operational characteristics  of converting a population of 
ESRD subjects from an injectable to oral anemia therapy  
Study  Design 
Overview:  Single -arm study  to evaluate  roxadustat  in correcting  or maintaining  Hb in 
ESRD subjects receiving chronic dialysis: 
• Either  after conversion from  a stable  CERA  dose:  
CERA  use > 6 weeks  prior to conversion to roxadustat dosing  
• Or as initial anemia treatment,  in subjects  with < 6 weeks  of CERA 
use or no prior ESA use prior to start of roxadustat dosing 
The study periods are as follows:  
o Screening  Period:  Up to 6 weeks  
o Treatment  Period:  [ADDRESS_664639]-Treatment  Follow- Up Period : Subjects  permanently 
discontinuing roxadustat should have one final safety 
assessment [ADDRESS_664640] 8 weeks prior to conversion 
(See Table S1 ). 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  12 of 74  
  
 Roxadustat  treatment  should  start two weeks  after stoppi[INVESTIGATOR_513327]  (< 6 weeks  of prior CERA  use),  the 
initial roxadustat dose is based on estimated dry weight at enrollment (See 
Table S2 ). 
Roxadustat dose adjustments  should follow the Dose Adjustment Rules,  to 
maintain Hb within the target range specified in Table S3 ). 
During the Treatment  Period, subjects  will attend  biweekly  study visits  from 
Day 1 to Week 8, followed by [INVESTIGATOR_135] 4-week study visits from Week 8 – 24. Local Hb valu es will be drawn, prior to dialysis, in order to determine the 
need for a dose adjustment, and to assess for excessive rate of hemoglobin rise, in real -time.  
After  completing  the Treatment  Period  (Week  24 /EOT),  subjects who wish 
to permanently discontinue roxadustat, should receive the first ESA dose at least two days after the last roxadustat dose. Subjects permanently discontinuing roxadustat should also have one final safety assessment [ADDRESS_664641].  
Guidelines  for patients  receiving  home- dialysis:  
Home -dialysis  patients  are allowed  to participate  in this study. Investigators 
may use delivery services for medication dispense and/or local laboratory blood draw and/or testing. For home-dialysis patients, investigators may adjust study visit frequency and method of visits  such as use of telemedicine including dose-dispensation 
schedule in consideration of clinical circumstances and convenience of the patient.  
To simplify  the study procedures  for home- dialysis  patients,  renal  ultrasound 
can be exempted, Screening Visit and Day [ADDRESS_664642] visit researc h-center during 
Screening/Day 1, and Week 24 (or if discontinued prematurely) and clinical laboratory testing for these visits need to be sent to the central lab. For other visits (per SOA), investigator/authorized study staff should contact [CONTACT_513344] a telemedicine, such as phone (audio, video call etc.) to collect 
study related information e.g. documentation of study drug dose, 
hemoglobin level,  adverse events  including hospi[INVESTIGATOR_059],  conmed  changes, 
transfusion etc, and to provide instructions on study drug dose adjustments. When possible, investigator should make efforts to combine standard of care visits to the clinic with the study visit that falls around that time frame (out of window protocol deviation will be exempted) in order to perform in- center assessments, central laboratory draws as deemed necessary by [CONTACT_513345].  
Hemoglobin levels every 2 to 4 weeks (as part of CBC listed in SOA) are needed  for dose adjustments  of roxadustat. The hemoglobin testing  between 
Weeks 2 to 24 may be conducted via central lab, local lab, or validated  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664643] results  need  to be made available to the study 
file. 
Combining  Screening  and Day 1 visits:  
Laboratory values related to eligibility assessments (e.g. LFTs, Hepatitis B and C, HIV, serum pregnancy, CBC/Hb, iron parameters) performed at a local lab within 12 weeks prior to enrollment/Day 1 may be used instead of central laboratory values (done during screening) to confirm eli gibility, if 
available. If local laboratory values are not available, Screening and Day [ADDRESS_664644] considering the current clinical condition and convenience of the patient. Upon reviewing central lab values collected  at Day 1, PI [INVESTIGATOR_513328] (e.g. very high LFT values). 
Inclusion 
Criteria:  A subject  is eligible  for the study  if all of the following  criteria  are met: 
1. Subject  has been  informed  of the investigational nature of this study and 
has given written informed consent in accordance with institutional, local, and national guidelines 
2. Subject  is ≥ 18 years of  age 
3. Receiving  chronic dialysis for end stage renal  disease  (ESRD)  
4. Prior ESA  use: 
• Fo
r  a subject  converting from  an ESA : On CERA  ≥ 6 weeks  and the 
prescribed CERA dose should remain stable (as determined by [CONTACT_976]) during the 4 weeks prior to initiating roxadustat treatment  
• Subject  is in
 itiating  anemia treatment: Defined  as: < [ADDRESS_664645] be a functioning native arteriovenous fistula or graft  with adequate flow in the opi[INVESTIGATOR_871], or permanent 
tunneled catheter.  
6. Screening  Hb (based  on central  lab value;  measured  within  10 days prior 
to initiating roxadustat treatment):  
• S
ubjects  converting from  an ESA : screening  Hb is between  9.0 to 
12.0 g/dL  
• S ubjects  initiating  anemia treatment : screening  Hb is < 10.0 g/dL 
7. Ferritin  ≥ 50 ng/mL, Transferrin  saturation  (TSAT)  ≥ 10% at screening 
(subject may qualify after receiving iron supplement per local standard of care)  
8. Subject’s  alanine aminotransferase (ALT)  and aspartate aminotransferase 
(AST) are ≤ 3 x upper limit of normal (ULN), and total bilirubin (TBL)  
is ≤ 1.[ADDRESS_664646] at screening and prior to initiating roxadustat treatment. (TBL up to [ADDRESS_664647] and ALT are with in normal 
limit)  
9. Subject’s  body weight (estimated  dry weight in HD subjects)  is 45.0 to 
160.0 kg 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  14 of 74  
  
Exclusion 
Criteria:  Subjects  will be excluded  if any of the following  criteria  are met: 
1. Subject  has received  a red blood cell (RBC)  transfusion within  [ADDRESS_664648]  has a known hereditary  hematologic disease such as thalassemia 
or sickle cell anemia, pure red cell aplasia or other known causes for 
anemia other than chronic kidney disease (CKD) 
4. Subject  has known hemosiderosis, hemochromatosis, coagulation 
disorder, or hypercoagulable condition 
5. Subject  has a known chronic  inflammatory  disease  that is determined  by 
[CONTACT_464456] (e.g., systemic lupus erythematosus, rheumatoid arthritis, celiac disease)  
6. Subject  is anticipated  to undergo elective  surgery  that is expected  to lead 
to significant blood loss during the study period or anticipated elective coronary revascularization. 
7. Subject  has active or chronic gastrointestinal bleeding 
8. Subject  has been  treated  with iron-chelating  agents  within  [ADDRESS_664649] has a history of chronic liver disease (e.g., chronic infectious hepatitis,  chronic auto-immune liver disease,  cirrhosis,  or fibrosis  of the 
liver)  
10. Subject  with New  York  Heart  Association  (NYHA)  Class  III or IV 
congestive heart failure 
11. Subject  has had an MI, acute coronary syndrome, stroke, seizure,  or a 
thrombotic/thromboembolic event  (excluding vascular  dialysis  access 
stenosis/thrombosis) (e.g. DVT or pulmonary embolism) within [ADDRESS_664650] has a diagnosis or suspi[INVESTIGATOR_2798] (e.g., complex kidney cyst or Bosniak Category  II or higher) of renal  cell carcinoma 
(PI’s  discretion) 
14. Subject has a history of malignancy, except for the following: cancers determined  to be cured  or in remission  for ≥ [ADDRESS_664651]  is positive for any of the following:  
• Human  immunodeficiency virus (HIV)  
• Hepatitis  B surface  antigen  (HBsAg)  
• Anti-hepatitis  C virus antibody (anti-HCV Ab) 
16. Subject  has an active,  clinically  significant infection  at the time of 
enrollment as determined by [CONTACT_093] 
17. Subject has any of the following known untreated conditions as determined by [CONTACT_093]: proliferative diabetic retinopathy, 
diabetic  macular  edema,  macular  degeneration  or retinal  vein occlusion 
(subjects who are already blind  may qualify to participate)  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664652]  one of the following 
conditions or states 
a) Experienced  rejection  of transplanted  organ within  6 months of 
transplantation  
b) Currently  on high doses of immunosuppressive therapy (per 
discretion of the investigator) 
c) Are scheduled  for organ  transplantation (on the waiting  list for kidney 
transplant is n ot exclusionary) 
19. Subject  has participated  in an interventional clinical study or has been 
treated with  an investigational drug within [ADDRESS_664653] has drug-treated gastroparesis, short-bowel syndrome, or any 
other gastrointestinal condition that may lead to reduced  absorption of 
study drug (determined by [CONTACT_093]) 
21. Subject has an anticipated use of dapsone or androgen in any dose amount or anticipated  chronic use of acetaminophen  or paracetamol  
> 2.0 g/day during the study  
22. Subject  has a history of alcohol or drug abuse within  6 months prior to 
screening as determined by [CONTACT_464457] 
23. Females  of childbearing potential,  if not practicing  complete  sexual 
abstinence or using contraception as detailed in the protocol; male subjects (if not surgically sterile; i.e., no vasectomy) with sexual partners  of childbearing potential,  if not practicing  complete  sexual 
abstinence or using contraception 
24. Pregnant or breastfeeding females  
25. Subject  has any medical  condition that in the opi[INVESTIGATOR_513329] a safety risk  to the subject in this study, which may confound 
efficacy or safety assessment, or may interfere with study participation  
Study 
Procedures:  See Schedule  of Assessments  (Appendix  2) 
Investigational 
Product  Roxadustat  tablets  may be available  in 20, 50, 70, [ADDRESS_664654] be administered whole.  
Route  of Administration:  Oral (all tablets  must be administered  whole)  
Dosing Frequency: Subjects will be dosed three times weekly (TIW), 
except  if a subject  requires  < 60 mg/week  to maintain  Hb levels,  in which 
case dose frequency may be reduced in a stepwise fashion, e.g., to twice weekly (BIW), then once weekly (QW). 
Initial Doses:  
• Conversion from  CERA to Roxadustat:  
The initial roxadustat dose is determined using a conversion table based on 
the subject’s  prescribed  ESA  dose in the last 4 weeks  prior to enrollment (for 
Mircera
®:in the last 8 weeks prior to enrollment) ( Table S1 ). 
Roxadustat treatment  should start two weeks  after stoppi[INVESTIGATOR_513330] 3.0 mg/kg/dose 
then the next -lower dose step should be chosen as the initial dose.  
DocuSign Envelope ID:F8E78CBE -578F -461D -BCDA -949A802CD9B4
Roxadustat Protocol FGCL -4592 -097A2
Confidential Page 16of74L
Current Hblevel:
<10.5 g/dL 10.5 to11.9 g/dL 12.0 to12.9 g/d ≥13.0 g/dL
>1.0g/dL
-1.0g/dL to
+1.0 g/dL
<-1.0g/dL Nochange* ↑ ↑↓ Nochange ↑•Hold dosing
•Check Hb and
resume dosing when
Hb <12.0 g/dL, at adose reduced by 2
steps↓ ↓ NochangeIf a subject is on ESA dose hold for high haemoglobin during screening, 
enrollment should be delayed  until the subject is ready toresume anaemia 
treatment.  Upon enrollment, all subjects  must initiate  roxadustat at Day  1. 
Table S1: Conversion from ESA to Roxadustat 
Previous Dose ofMircera®
(mcg/month)Starting Dose ofRoxadustat
(mg/dose TIW)
<80 70
80to120 100
121to200 150
>200 200
•Initiation  of Roxadustat in subjects with  < 6 weeks  of prior 
CERA use or no prior ESA use:
Initial roxadustat dosing is based  on broad body weight categories (estimated 
dry weight at enrollment): Table S2: Initial Roxadustat Dosing:
Body Weight Category < 100kg ≥100kg
Roxadustat Dose (TIW) 70mg 100 mg
Note: Weight inHDsubjects  = subject’s estimated  dry weight atenrollment.
Dose Adjustments:
During the Treatment Period, roxadustat dose adjustment will be made starting at Week  4 and at intervals  of every  4 weeks thereafter  according to 
the dose adjustment algorithm below, in order to achieve an Hblevel  of 11 
g/dL and maintain an Hb of 11±1 g/ dL: 
Table S3: Dose Adjustments : 
↑:Increase dose by[CONTACT_513346];↓: reduce dose by [CONTACT_80946].
*Continue tohold dose
Dose  adjustment steps:  20, 40, 50, 70, 100, 150, 200, 250, 300 and 400 mg
If Hb increases by >2.0 g/dL within a 4-week period, reduce dose by [CONTACT_80946] . 
Roxadustat dose adjustment reviews  should occur every  4 weeks, except if 
the following criteria are met:
•Rate of Hb rise > 2 g/dL within  4 weeks: reduce dose by 1 dose stepChange inHbover
previous 4weeks:
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  17 of 74  
  
 • Hb level > 13g/dL: hold dose, check Hb weekly or as deemed 
necessary  by [CONTACT_513347] < 12g/dL, resume  dosing 
at 2 dose steps lower  
Dose adjustments or temporary dose holds for excessive rate of Hb rise or 
Hb 
above 13 g/dL can occur at any time during the Treatment  Period. Any 
dose adjustment will reset the dose -adjustment window to every 4 weeks 
thereafter (e.g., dose adjustment for a qualified reason at Week 6 leads to next dose adjustment at Week 10). 
Prescribed  dose must not exceed  the maximum allowable  dose of 
3.0 mg/kg/dose or 400 mg per dose, whichever  is lower.  Estimated  dry- 
weight at enrollment should be used f or the entire treatment period.  
Rescue  Therapy 
and Emergency 
Procedures:  Rescue  Therapy  Guidelines:  
Rescue therapy  guidelines are provided to optimize  the standardization of 
rescue therapy, and to ensure the safety of individual study subjects. 
Red Blood Cell Transfusion (for all subjects)  
RBC transfusion should be considered if rapid correction of anemia is 
required to stabilize the subject’s condition (e.g., acute hemorrhage) or the Investigator is of the opi[INVESTIGATOR_167384] a medical necessity.  If the situation  permits,  the Medical  Monitor should be informed 
prior to any scheduled RBC transfusion. Study treatment may continue during or after the RBC transfusion. 
Erythropoiesis  Stimulating  Agent  (ESA) Use 
If possible, the use of ESAs as a “Rescue” modality should be carefully 
considered, and should be restricted  to no more  than one cycle  of use during 
the Treatment Period; the Investigator may initiate use of an approved erythropoietin (EPO) analogue if all of the following criter ia are met:  
• A subject’s Hb level has not sufficiently responded to two or more 
dose increases  or the maximum dose of study drug has been  reached, 
and 
• The subject’s  Hb is < 8.5 g/dL on two consecutive measurements  at 
least five days apart; and  
• Clinical judgment does not suggest iron deficiency  or bleeding as a 
cause of lack of response or rapid decline in Hb, and 
• Reducing the risk of alloimmunization  in transplant eligible  subjects 
and/or reduction of other RBC transfusion- related risks is a goal 
Such  ESA  Rescue should be started  ≥ [ADDRESS_664655] dose of 
roxadustat.  
ESA Rescue should be stopped when Hb > 9 g/dL or after 4-weeks, whichever  comes  first. If a subject  requires  longer than 4-weeks  therapy  due 
to inadequate response, or in other extenuating circumstances, the Medical Monitor should be contact[INVESTIGATOR_530]. 
Study treatment  should be resumed  after the following  intervals:  
• Two days after stoppi[INVESTIGATOR_167385]  
• One week  after stoppi[INVESTIGATOR_167386] 
• Two weeks  after stoppi[INVESTIGATOR_167387]- epoetin  beta 
(Mircera
®) 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  18 of 74  
  
 If more  than one cycle  of ESA  rescue  is required,  the Investigator  should 
permanently discontinue study drug. 
Inadvertent ESA administration, such as ESA administration during a 
hospi[INVESTIGATOR_059], should not be counted as rescue unless above criteria are met; these subjects  may be allowed  to restart  roxadustat dosing if considered 
safe by [CONTACT_47998]. All ESAs  used during the Treatment  Period, either  planned or inadvertent, 
should be recorded. ESAs  and Roxadustat should not be administered  concomitantly.  
 
Emergency  Procedure (Therapeutic Phlebotomy)  
If there are clinical  concerns  for a subject’s  high Hb  levels,  the Investigator 
may decide to perform  a therapeutic  phlebotomy in addition to temporarily 
withholding the study drug. This  should be documented  and discussed  with 
the Medical Monitor.  
IV Iron  Use: Intravenous  Iron  Supplementation  
Intravenous iron should be considered for subjects with ferritin  <200 ng/mL 
or TSAT <20%. 
In this study, oral iron may be administered  for iron supplementation without 
restriction. Dose and frequency of administration of oral iron are to be 
determined by [CONTACT_093].  
Prohibited 
Medication:  The following  medications/therapi[INVESTIGATOR_513331]:  
• Any investigational drug from  4 weeks  prior to screening  until EOS 
• Androgens from  screening  until EOS 
• Iron-chelating agents (e.g., deferoxamine/desferrioxamine, 
deferiprone,  or deferasirox  therapy) from  4 weeks  prior to enrollment 
until EOS  
• Dapsone (at any dose) from  screening  until EOS 
Chronic doses acetaminophen/paracetamol  > 2.0 g/day  from 
enrollment until 1 week after EOT  
Efficacy 
Endpoints  and 
Assessments:  Efficacy  Endpoints:  
• Proportion of subjects  with mean  Hb > 10g/dL, averaged  from  Week 
16 through Week 24. 
• M ean  Hb change from  baseline to average Hb from  Week  16-Week 
24 
 
Exploratory Endpoints/Analyses:  
• Time  to first RBC transfusion 
• Proportion of patients  with a mean  Hb levels  ≥10 g/dL  in the first 8 
weeks after conversion  
• Proportion of patients  with mean  Hb level  ≥10 g/dL based  on 
baseline ESA  use status  (≥ 6 weeks  and < 6 weeks)  
• Evaluate the utilization  of intravenous (IV) iron (IV iron use/4  weeks)  
• Evaluate the effect  on iron indices  
• Evaluate dosing adherence 
• Conversion  subjects:  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  19 of 74  
  
 o Comparison  of starting  dose of roxadustat  to roxadustat 
dose at Week 16 -24 
• Mean  number of dose adjustments during study  
Safety 
Assessments and 
Endpoints:  Study -specific  safety  will be assessed  by [CONTACT_2889]:  
• Incidence of treatment  emergent  adverse events  (TEAEs)  and 
treatment emergent serious adverse events (TESAEs)  
• Clinically  significant changes  in laboratory values  from  baseline  
• Vital  signs  
Statistical 
Methods:  Stratification:  Not applicable  
Sample  size determination:  
Approximately 200 subjects with anemia of CKD (either with or without 
treatment  with ESA  at enrollment)  and on hemodialysis are planned  in this 
study. This number of subjects distributed across the specified number of sites is adequate to evaluate the primary study objective.  
Assuming the proportion of subjects that maintain Hb levels ≥10g/dL from Weeks [ADDRESS_664656] 80%, with a sample size of 200, the study will be able to produce a two-sided  95% confidence interval (CI) with a width  equal 
of 11.5%. 
Analysis Sets:  
The FAS set will consist of all subjects  who signed informed  cons ent, who 
were enrolled,  and who provided baseline Hb data and  data for at least one 
post baseline Hb time point. The FAS set will be used for all efficacy 
endpoints and analyses. The Safety  analysis  set will include all enrolled  subjects  receiving  at least 1 
dose of study treatment. The safety analysis set will be used for all safety endpoints and exposure to study treatment outcomes. Efficacy  
 analyses : 
The efficacy  endpoint will be evaluated  using the proportion (%) of subjects 
with mean value of Hb measurements of > 10g/dL from Week 16 through 
Week 24.  
For the efficacy analysis, a multiple imputation (MI) method will be used. T
his will be implemented on the raw Hb values, then the endpoint will be 
derived  based  on the i mputed  data (algorithm as used for the previous phase 
3 studies). For continuous endpoints, changes  from  baseline will be presented 
descriptively.  
Proportion of responders will be presented  descriptively  with count and 
percentages and 95% confidence interval of the responder rate. Time  to response will be analyzed  using the Kaplan -Meier  method with KM 
curve plotted. 
Safety:  
The safety analyses will be performed using the Safety Analysis Set (SAF). 
Safety  parameters  include TEAEs,  TESAEs,  laboratory parameters  and vital 
signs.  
The number and percentage of subjects reporting treatment -emergent  AEs 
(TEAEs) and TESAEs will be tabulated.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  20 of 74  
  
 Descriptive  statistics  will be presented  for laboratories  and vital signs.  
This study will be conducted  in accordance with the guidelines of Good Clinical Practice and the 
applicable regulatory requirement(s), including the archiving of essential documents. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  21 of 74  
 2. BACKGROUND  
Hypoxia- inducible factor (HIF) is a key transcri ption factor that coordinates the body’s physiological 
response to changes in oxygen levels in the cellular environment ( Semenza, 2000) . It induces the 
expression of erythropoietin (EPO) and the EPO receptor, as well as the expression of other proteins 
that promote iron absorption and recycling  (Peyssonnaux et al, 2008) . The activity  of HIF is regulated 
by [CONTACT_68413]-inducible factor prolyl hydroxylase (HIF- PH) enzymes (HIF -PHD1 to D3). These 
enzymes target HIF for degradation.  
Roxadustat (FG-4592/ ASP1517/ AZD9941) is an orally active novel small- molecule that inhibits 
these HIF -PH enzymes. By [CONTACT_270152]-PH, roxadustat stimulates erythropoiesis via the HIF 
pathway  in a manner  consistent  with the body’s normal  response to hypoxia. Its ability  to stimulate 
erythropoiesis makes it a candidate for the treatment of anemia associated with chronic kidney disease (CKD) in patients with nondialysis-dependent (NDD-CKD) and dialysis-dependent 
(DD-CKD) . 
 
2.1. Introduction  
2.1.1. Epi[INVESTIGATOR_464441]-Stage Renal  Disease  
Chronic kidney disease is a growing worldwide public health problem. It is associated with 
significant morbidity and mortality, yet is underdiagnosed and undertreated. It is characterized by [CONTACT_167408], resulting  in premature death  or renal  replacement  therapy  (RRT) 
(kidney transplant or dialysis). 
The average prevalence of CKD, regardless of age, ranges between 3% -17% in Europe and the all - 
cause mortality  risk increases  exponentially as CKD stages  advance ( Bruck  K, et al). The prevalence 
of DD -CKD is 887 per million people in China (2011 Shanghai Dialysis Registry Report) and in  the 
US, CKD affected 13% of the US adult population (~ 29 million adults) in 2007, and the prevalence 
is rapi[INVESTIGATOR_464442] ( Coresh et al., 2007) and worldwide ( Xie Y, et al ). In Europe, the 
average prevalence of CKD regardless of age lies between 5 and 11% ( Zoccali et al., 2010 ). 
The number of patients suffering from end- stage renal disease (ESRD) also continues to increase 
worldwide. The US has one of the highest prevalence rates of ESRD in the world: in 2010, the US had over [ADDRESS_664657] per million population, a 23% increase compared to 10 years before (USRDS, 2011) . In 2009 (point prevalence as of December 31st), the re were approximately 
570,[ADDRESS_664658]  in the US, of whom 370,000 were receiving  hemodialysis (HD),  27,000 
were receiving peritoneal dialysis (PD), and 173,000 had a functioning kidney transplant 
(USRDS, 2011). In recent years, those older than [ADDRESS_664659]  (1735 per million  populations in 2007, US by [CONTACT_270153]/ethnicity).  The 
adjusted ESRD incidence rates were 998 per million populations for African Americans, 396 per million population for Asians/Pacific Islanders, and 273 per million populations for whites in 2007 (USRDS, 2009) . In Europe, over the period 1992–2005, the overall crude prevalence of RRT for 
patients  with ESRD  increased  from  480 to 807 patients  per million  populations (Zoccali  et al., 2010). 
The average expected life expectancy of a dialysis patient is 5.9 years, compared to 16.4 years for a t
ransplant patient,  and 25.2 years  for someone of comparable age in the general  population (USRDS, 
2009). The prevalence of ESRD is projected to grow to 774,000 by [CONTACT_2892] 2020 (USRDS, 2009). 
Data from  selected  countries in  Europe indicate  that the 5- year mortality  rates  in incident patients  on 
RRT  are 52% in all patients,  and 21%, 32% and 73%  for patients  0 to 14, 15  to 64 and over 65 years 
of age, respectively (Zoccali et al., 2010). 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  22 of 74  
 2.1.2. Anemia  Associated  with  Chronic  Kidney  Disease  
Anemia is a common complication in patients with CKD, and although its pathogenesis is 
multifactorial, the decreased production of EPO, a hormone produced primarily in the kidneys, is considered  an important etiologic  factor.  The impaired  ability  of the body to absorb and utilize  iron is 
likely a second etiologic factor. 
Anemia may present in the early stages of CKD and its prevalence increases as CKD progresses. 
Anemia is present in 17% of patients with late Stage 3 disease; this increases to 25% in patients with Stage 4 disease,  and to 49%  in patients  with  Stage  [ADDRESS_664660] not yet  progressed to  requiring 
dialysis ( Coresh et al., 2007; Go et al., 2004) . Over 90% of patients undergoing dialysis are anemic. 
Half of all patients new to dialysis (50.1%) have hemoglobin (Hb) levels below 10 g/dL and approximately 28% have Hb levels  below 9 g/dL (USRDS,  2003) . Some studies  from  Europe provide 
data on anemia rates in patients who have been under care of nephrologists. In 1999, Jungers prospectively studied 403 consecutive ambulatory predialysis patients and  found that 60% of patients 
with a creatinine clearance of < 20 ml/min/1.73  m2 were anemic (Hb < 11 g/dL) ( Jungers et al., 
2002) . Between 2003 and 2005, Thilly studied predialysis anemia care in 6271 incident dialysis 
patients. The average level of predialysis Hb was  10.3 g/dl, and 63.6% of the patients had a Hb value 
lower than 11 g/dl ( Thilly et al., 2008) . 
The clinical consequences of anemia in patients with CKD have been studied extensively. Because 
the main  impact  of anemia on organ function is reduced  oxygen delivery  to tissues,  it affects  almost 
every organ system. 
Anemia is associated with excess morbidity and mortality in patients with CKD and ESRD. In 
patients with CKD, the severity of anemia correlates directly with the risk of hospi[INVESTIGATOR_059], cardiovascular (CV) disease, and death ( Collins et al., 1998) . Anemia contributes to eccentric left 
ventricular hypertrophy and maladaptive remodeling of the left ventricle. Patients with  the lowest Hb 
have worse outcomes, as was discussed in the post hoc analysis of mortality by [CONTACT_513348] (CHOIR)  study in the 
Food and Drug Administration (FDA) briefing document for the October 2007 Cardiovascular and Renal Advisory Committee ( Unger,  2007) . Similar observations are found in the [LOCATION_002] Renal 
Data System (USRDS) mortality data stratified by [CONTACT_2894]. All- cause mortality stratified by [CONTACT_2894] (between 
the years of 1993 to 1996) indicated significantly higher first-year death rates in patients with Hb levels < 9 g/dL, compared to 11 to 12 g/dL. This trend continued to worsen, as reflected in USRDS data collected between 1998 1999 where the death  rate rose by ~75% compared to the 1993 to 1996 
period ( USRDS, 2000; USRDS, 2002) . This increase coincides with the introduction of the Kidney 
Disease Outcomes Quality Initiative (KDOQI) guide lines in 1997. The relative risk of all- cause 
mortality for patients with Hb < 9 g/dL is twice that of patients with Hb > 12 g/dL (USRDS, 2002). 
The relative risk ratio of CV  hospi[INVESTIGATOR_464443] 1.26 in patients  with Hb levels  
<9 g/dL compared  to those with Hb at 11 to 12 g/dL (USRDS,  2001) . 
Multiple  studies have suggested  that treatment of anemia  reduces  the need  for blood transfusions and 
improves health- related quality of life (HRQoL) ( NKF K/DOQI, 2007 ). 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664661]  of care for CKD  or DD-CKD  Anemia  
Today, therapy with erythropoiesis -stimulating agents (ESAs) is a major alternative to transfusion in 
managing anemia associated with CKD. For those not resistant to ESAs, parenteral administration of 
exogenous recombinant human EPO (epoetin alfa or beta) or pegylated analogues has been a widely accepted  approach  for the  treatment  of anemia  in patients  with  CKD ( Winearls  et al., 1986; Eschbach  
et al., 1987; Eschbach et al.,1989a , Eschbach et al. 1989b) , despi[INVESTIGATOR_167390]. 
These safety risks include hypertension, thrombosis, and cerebrovascular events which may be associated  with supraphysiologic plasma  EPO  levels  frequently  observed  with ESA  therapy. Anemic 
patients with CKD or ESRD will require life -long treatment with these agents.  
Although the treatment of anemia in CKD and ESRD is thought to contribute positively to a patient’s quality of life, several studies in subjects with ESRD  and NDD -CKD have shown higher mortality or 
trends in that direction in the higher-dosed ESA-treated cohorts when the protocol objective was to 
treat one of the cohorts to high, almost normal target Hb levels ( Besarab et al. , 1998; Drueke et al.,  
2006; Singh et al., 2006) . An ESA dose relationship to mortality has been reported in a review of the 
USRDS database ( Zhang et al., 2004) of ESRD patients who received higher ESA doses, particularly 
in those more anemic (i.e., Hb < 11 g/dL). The FDA has recognized these excess morbidity and mortality risks (FDA, 2007). Updated product labeling for the approved ESAs in 2007 include a 
boxed warning of greater risk of death and CV events when ESAs are administered to target high Hb 
concentrations (≥ 13.5 g/dL) compared with lower Hb targets. The FDA also acknowledged the potential off- target effect of ESAs contri buting to excess mortality due to CV events and thrombosis 
(Unger, 2010 ). The currently approved ESA labeling directs prescribers to target Hb levels of 10 to 
11 g/dL in the US and 10 to 12 g/dL outside the US. The literature on this topic, including meta- analyses, supports the view that the AEs associated with ESAs are typi[INVESTIGATOR_513332]  (Zhang et al., 2004; Unger, 2007; Szczech,  2008; Fishbane and Beserab,  2007; 
Besarab et al., 2009) . Posthoc analyses of three major RCTs, ( Kilpatrick et al., 2008; Szczech, 2008; 
Solomon et al., 2010) NHCT, CHOIR, and TREAT, indicates that outcomes correlate with  
“achieved” and not “target” Hb levels.  
Additionally, some patients  are hyporesponsive to ESA  therapy. A significant proportion (~ 17%) of 
DD-CKD patients require stable ESA dosing at 2 to 6 times the median seen in the entire CKD 
population (150 to 450 U/kg of IV  epoetin TIW). This “hyporesponder” patient population accounts 
for approximately 50% of epoetin alfa consumption in the US (Besarab et al., 2009). This is a 
significant economic burden, and as noted above, higher doses of ESAs have been associated with higher rates of morbidity and mortality (Zhang et al., 2004; Unger, 2007; Szczech, 2008). Thus, this patient population has the greatest need for an effective and safe therapy for anemia. In turn, the increasing perception that high ESA dosing is associated with significant risk, especially in patients not achieving  target,  is expected  to lead to lower  ESA  dosing and an associated  higher prevalence of 
patients with low Hb levels. In December of 2007, 2.1% of patients had Hb levels < 9 g/dL, 7% had Hb levels < 10 g/dL, and 21.6% did not reach 11 g/dL, while 34.8% were 11 to 12 g/dL ( USRDS,  
2009) . Hb levels < 11 g/dL in this population are associated with increased mortality and 
hospi[INVESTIGATOR_14285], and failure to achieve a Hb level > 11 g/dL is a prognostic indicator of poor outcomes ( Ma, 1999; Regidor, 2006) . In patients with persistently low Hb levels, mortality risk is 
strongly associated with the patient's ability to achieve a hematopoietic response ( Bradb ury, 2009 ). 
Additionally, ESA  therapy  for anemia in patients  with ESRD  on HD usually requires  concomitant IV 
iron supplementation to avoid functional iron deficiency and epoetin dose escalation; however; IV 
iron use is not without risk. However, as reported by [CONTACT_270154] ( USRDS, 2013) , a
 dministration of 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  24 of 74  
 IV iron is a t an all -time high. Among patients on HD, the transfusion rate, at 2.7% to 2.9% at the 
beginning of 2010, reached  3.3–3.[ADDRESS_664662] six months of 2012. Among patients  on PD, 
the rate has increased from 2.3 –2.9 to 3.0–3.9. 
There is  currently an unmet medical need for an  oral treatment that can correct anemia in patients 
with NDD- CKD and  DD-CKD while  avoiding supraphysiologic levels  of circulating  plasma EPO 
levels.  
Roxadustat is an oral medication that could potentially deliver effective treatment for CKD -related 
anemia with less need  for IV iron supplementation and without producing supraphysiologic levels  of 
circulating  EPO, which may translate into an improved safety profile. Roxadustat is being evaluated 
as a potential alternative treatment for anemia in subjects with NDD -CKD and DD- CKD.  
 
2.3. Mechanism  of Action  of Roxadustat  
Virtually all tissues depend on a sufficient supply of oxygen for survival. Lack of oxygen associated 
with hypoxic, ischemic, and anemic conditions triggers a series of homeostatic responses (Figure 1). 
Hypoxia-inducible factor is a transcription factor that is believed to be the key element in the body’s oxygen sensing mechanism  (Semenza,  2000) . Hypoxia-inducible factor  regulates  expression of genes 
that modulate both the acute and chronic response to hypoxia, and HIF-responsive genes regulate processes as diverse as erythropoiesis, iron metabolism, oxidation, cellular metabolism, glycolysis, vasculogenesis, cell cycle pr ogression, and apoptosis. Chronic hypoxia and intermittent hypoxia 
induce different  sets of genes  associated  with HIF transcriptional activity  (Fan et al., 2005) . Hypoxia- 
inducible factor is a heterodimeric transcription fa ctor family comprising three oxygen- sensitive 
isoforms (HIF 1α, HIF -2α and HIF -3α), and a constitutively expressed HIF -1β subunit, with each 
heterodimeric isoform responsible for the induction of specific sets of genes ( Greijer et al.,2005;  
Hu et al., 2003) . For example, HIF -1α has been shown to regulate vascular endothelial growth factor 
(VEGF)  expression  (Gray  et al., 2005; Buchler  et al., 2003) , while  HIF 2α is critical  for the induction 
of the EPO gene and erythropoiesis ( Warnecke et al., 2004; Scortegagna et al., 2005).  
Figure 1.  Hypoxia- Inducible  Factor Prolyl Hydroxylase Inhibitor  (HIF -PHI) 
Mechanism of Action  
 
Abbreviations:  DcytB = Duodenal cytochrome B; DMT1 = divalent metal transporter one; EPO = erythropoietin; HIF = hypoxia - 
inducible  factor;  HIF-PH = hypoxia -inducible  factor  prolyl  hydroxylase;  HIF PHI = hypoxia -inducible  factor  prolyl 
hydroxylase inhibitor; mRNA = messenger ribonucleic acid; Tf -R = Transferrin receptor; Ub = ubiquitin;  
VHL  = Von Hippel –Lindau  protein.  
Source:  Epstein,  et al , 2001  

DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664663] sensitive and well-studied HIF-responsive genes is the EPO gene. Increased transcription of the EPO gene leads to 
increased  circulating  levels  of EPO,  which  acts at sites of erythropoiesis to enhance the differentiation 
and proliferation of red blood cell (RBC) precursors. 
Although HIF-α isoforms  are constitutively  produced, their accumulation  under normoxic conditions 
is prevented by [CONTACT_167410]-Lindau (VHL) protein, which targets 
HIF-α isoforms for degradation through the ubiquitin-proteasome pathway. The molecular 
mechanism for oxygen-dependent degradation of HIF- α is based on the hydroxylation of specific 
proline residues, as catalyzed by a family of HIF-PHs that utilize molecular oxygen as the substrate 
for hydroxylation. Thus, HIF-PH constitutes the body’s main oxygen sensor by [CONTACT_513349]. Under hypoxic conditions, HIF PHs are inactive  and 
lead to initiation  of the HIF-responsive transcriptional cascade  (Wang  et al., 1995; Semenza,  1998 ). 
Roxadustat is a potent and reversible  hypoxia-inducible factor  prolyl hydroxylase inhibitor (HIF -PHI) 
that transiently induces HIF stabilization and leads to a functional HIF transcriptional response that mimics the erythropoietic response associated with exposure of humans to intermittent hypoxia. HIF 
induces expression of not only EPO, but also the EPO receptor and proteins that promote iron 
absorption and recycling from the macrophage iron storage system ( Peyssonnaux et al., 2008) . Thus, 
roxadustat pharmacologically stimulates erythropoiesis via the HIF pathway and in a manner consistent with  the body’s normal homeostatic  response to anemia,  but under normoxic conditions. In 
contrast to the classical paradigm, suggesting that anemia in CKD patients is caused by [CONTACT_167412], results of a study of roxadustat treatment of CKD subjects not requiring dialysis (Study FGCL-SM4592-017) suggest that the kidneys and other sites of EPO production in this patient population retain the ability to produce sufficient EPO for robust erythropoiesis.  
Roxadustat also has the potential to effectively treat anemia caused by [CONTACT_2898] -induced 
functional iron deficiency,  which  are typi[INVESTIGATOR_513333].  In these conditions, iron 
availability for erythropoiesis is reduced due to a number of inflammatory mediators. Because 
HIF-PHIs  such as roxadustat alter expression not only of the EPO  gene but also  of genes  regulating 
iron metabolism, it is postulated that roxadustat may be effective in treating these anemias as well 
(Langsetmo et al., 2005) . 
Chronic hypoxia and intermittent hypoxia induce different sets of genes associated with HIF 
transcriptional activity, presumably because intermittent stimulation allows the restoration of HIF degradation, turnover, and inactivation. Transient activation of HIF thereby  [CONTACT_513350], as well as 
expression of additional genes that are secondary to activation of HIF-dependent genes. Both nonclinical and clinical  studies of roxadustat have successfully  used the intermittent dosing paradigm 
to induce selective erythropoiesis and to optimize  the Hb dose response. Furthermore, roxadustat was 
selected for development over other HIF- PHI candidate molecules based on an optimal 
biodistribution profile  that enhances  its selective actions. The specific  tissues where roxadustat enters 
the cytoplasm and triggers gene expression reside in the main target organs for erythropoiesis: the 
kidney (EPO production), the bone marrow (increase in EPO receptors), the duodenum (transepi[INVESTIGATOR_2825]) , and the liver (EPO production, transferrin production, and 
down-r
egulation of hepcidin  production); roxadustat distributes  preferentially  to these organs.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664664] from 
that of ESAs, and these differences result in several potential advantages over ESAs beyond the 
convenience of oral therapy. These potential advantages include: 
• Increase in the number of EPO  receptors  in the bone marrow  
• Improved iron metabolism and bioavailability  
• Effective  erythropoiesis at nonsupraphysiologic plasma  EPO  levels  (10- to 20-fold lower 
than with parenteral ESA therapy) 
• Absence of hypertensive effect  
• Effective erythropoiesis in the presence of inflammation  
• Improvement in  lipid  profile  
2.4. Clinical Experience  with  Roxadustat  
In the recently completed global Phase [ADDRESS_664665] range of adult 
CKD patients (including both non- dialysis -dependent [NDD] and dialysis -dependent [DD] CKD 
populations) with anemia. Roxadustat was compared against placebo in three pi[INVESTIGATOR_464446] [ADDRESS_664666]  epoetin  alfa (standard  of care ESA)  in three pi[INVESTIGATOR_513334] 3880 patients. 
The effectiveness of roxadustat was consistently demonstrated across this wide spectrum of adult 
CKD patients, including NDD patients with baseline eGFR <15 mL/min/1.[ADDRESS_664667] to ESA comparator in maintaining Hb within intended target range in DD patients. Moreover, roxadustat-treated patients had lower risk of red blood cell transfusions compared  to placebo -treated  and epoetin  alfa-treated  patients  in the pooled 
NDD and DD CKD studies, respectively. Roxadustat also effectively treated anemia in patients whose baseline C -reactive protein (CRP), a marker of inflammation, was >ULN (roxadustat dosing 
was similar regardless if CRP was >ULN or <ULN), and roxadustat improved iron metabolism 
efficiency by [CONTACT_464467]. 
The safety of  roxadustat was evaluated against placebo in NDD  CKD studies and against epoetin  alfa 
in DD CKD studies. Incident dialysis (ID) patients (a sub-group of the overall DD population who 
initiated chronic dialysis with the past four months) who were treated with roxadustat had a lower risk of major adverse CV events (MACE defined as stroke, myocardia l infarction, all- cause death) 
and MACE+ (events that comprised MACE plus hospi[INVESTIGATOR_513335]), and a trend towards reduction of risk in all-cause mortality, compared with those who were treated  with epoetin  alfa. The overall  safety  profile  of roxadustat was comparable to placebo  for NDD 
CKD patients and comparable to epoetin alfa for DD and ID CKD patients with respect to most adverse events and serious adverse events. A number of adverse drug reactions (ADRs) were identified, including vascular access thrombosis, deep vein thrombosis, and seizures. Serious infection was considered an important potential risk, but causality was not established. No adverse hepatic risks from liver enzyme monitoring were identified, and t here were no clinically important 
changes in ECG parameters, including no evidence of QT prolongation. 
For detailed  safety  information, please refer  to the most current  version of the IB.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  27 of 74  
 2.4.1. Pharmacokinetics  and Pharmacodynamics  
The pharmacokinetics (PK) and pharmacodynamics of roxadustat were characterized in studies in 
healthy  volunteers and in dialysis  and nondialysis CKD subjects.  Roxadustat showed generally  dose 
proportional PK (except at the lowest dose of 0.3 mg/kg); t 1/2 was 12 to 14 hours in healthy 
volunteers, and  15 to  19 hours in  dialysis  subjects  (after a single 1 and  2 mg/kg dose). The exposure 
was higher in dialysis patients compared to healthy volunteers. Roxadustat can be administered before or after dialysis, sin ce the PK of roxadustat was not significantly altered when administered 
prior to the start of dialysis compared with after dialysis (Study FGCL-4592-039). 
A relative bioavailability study was conducted in 24 healthy volunteers comparing capsule 
formulation , which was used in Phase 1 and Phase 2 studies, with tablet formulation, which was 
developed for Phase 3. The study demonstrated bioequivalence to bridge the two formulations. With an intermittent dose regimen (once weekly [QW], twice weekly [BIW[ or three times a week [TIW]), no or limited accumulation in mean area under the concentration curve (AUC) or maximum 
concentration (C
max) was observed. Furthermore, no evidence was found for time-dependent PK (no 
auto-induction or inhibition). Roxadustat is highly protein bound and the PK of roxadustat is not 
affected  by [CONTACT_2900].  Metabolites  found in urine suggested Phase [ADDRESS_664668]. In plasma, parent roxadustat is the main component. The inhibitory potential of roxadustat 
on cytochrome P450 (CYP) enzymes, based on in- vitro studies is limited, and the lowest inhibition 
constant (Ki) value was observed for CYP 2C8 (16 μM). In a clinical drug-drug interaction study with rosiglitazone, a probe drug for CYP 2C8, roxadustat did not show any inhibitory potential on CYP 2C8 in vivo. 
In healthy adult male volunteers (Study FGCL-SM4592-016), roxadustat administered orally as a 
single dose up to 4.0 mg/kg, and QW, BIW or TIW for 4 weeks at doses up to 3.75 mg/kg, was 
pharmacodynamically  active  as evidenced  by [CONTACT_2715]-dependent transient  increases  in endogenous EPO 
(starting  from  single doses of 0.3 mg/kg), increases  in reticulocyte s (starting  from  doses of 2 mg/kg), 
and Hb responses (starting at 3 mg/kg). The mean peak level of plasma EPO following the Day 26 dose of 2.0 mg/kg TIW (the high therapeutic dose studied) was 326.3 ± 197.0 mIU/mL. 
In pharmacodynamic studies conducted with roxadustat in CKD subjects not on dialysis (Study 
FGCL -4592-017), the mean maximum EPO increase from baseline ranged from 82-443 mIU/mL and 
492-554 mIU/mL after a single 1 and 2 mg/kg dose, respectively. Results from PK studies in subjects on HD (Study FG CL-4592-039 in the US and Study CL-1517-203 in Japan) showed similarity in PK 
and pharmacodynamics  of roxadustat in Caucasians  and Japanese subjects  with  ESRD,  and the timing 
of roxadustat dosing relative to dialysis (given before or after dialysis) did not impact the PK profile. Also, comparable dose-dependent increases in EPO levels were observed with both pre and postdialysis dosing. These increases in endogenous EPO (eEPO) were transient, peaked at around [ADDRESS_664669],  EPO  levels  associated  with therapeutic ESA  dosing range from  1,500 to over 
10,000 mIU/mL ( Besarab et al., 2009) . In a clinical study with dialysis subjects, the reported mean 
administered  individual ESA  dose was 8,000 IU,  which  would correspond to  plasma  EPO  C
max levels 
exceeding 3,000 mIU/mL ( Fishbane and Besarab, 2007) . This is approximately 10-fold higher than 
the physiologic range. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664670]  patients  with anemia who converted  to roxadustat from  stable  ESA  and patients  who 
never used ESA before. These dosing schedules effectively corrected anemia and or maintained Hb levels close to 11.0 g/dL. 
Analysis of the Hb time course after initiation of treatment with roxadustat in patients previously not 
on ESA treat ment stratified by [CONTACT_513351] 70 mg for patients  with a body weight of <100 kg, and 
100 mg for patients with  a body weight of ≥100kg. The  proposed dose adjustment algorithm,  applied 
every 4 weeks, effectively maintained Hb levels close to 11.0 g/dL in these patients. 
For patients previously treated with an ESA, the applied starting doses of roxadustat (based on the 
conversion table)  in conjunction with  the dose adjustment algorithm resulted  in Hb levels  that were 
maintained  close to 11.0 g/dL. The full dose range of [ADDRESS_664671]’s average prescribed 
ESA dose in the last 4 weeks prior to enrollment if on epoetin or darbepoetin (8 weeks if on 
Mircera
®). 
Using the conversion table ( Table 1 ), in this study, subjects will receive starting roxadustat doses of 
70 mg, 100 mg, 150 mg, or 200 mg. If the converted initial dose exceeds the maximum dose of 3.0 
mg/kg/dose then the lower dose step should be chosen as the initial dose. Roxadustat doses will be administered at a frequency of TIW.  If a subject requires < 20 mg TIW (i.e., < 60 mg per week) to 
maintain  a Hb level  of 11±1 g/ dL, the dosing frequency  should be reduced  in a step-wise fashion e.g. 
TIW to BIW, BIW to QW, QW to Q -2 Week etc.  
 
2.6.1. Maximum Dose  for Roxadustat  
The maximum allowed roxadustat dose in this study is set at 400 mg or 3.0 mg/kg/dose (based on 
estimated  dry weight at enrollment in subjects  on HD),  whichever  is lower.  The highest dose tested  in 
healthy subjects is 5 mg/kg single dose and 3.75 mg/kg TIW. The doses were safe and well tolerated 
with transient dose-dependent HR increases observed. No maximum tolerated dose (MTD) was reached in the clinical development of roxadustat based on the observed pharmacodynamic response (plasma EPO levels) and the predicted relation between EPO levels and Hb response; therefore 
exploration of higher doses was not deemed necessary. Plasma EPO levels increased in a supralinear 
manner  with increasing  roxadustat doses. In Phase 3 dialysis studies, the full dose range of 20 to 400 
mg TIW was utilized.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664672] not exceed  the maximum allowable  dose of 3.0 mg/kg/dose or 400 
mg per dose, whichever is lower. 
 
2.7. Risks/Benefits of Roxadustat  Treatment  
The primary  benefit of roxadustat is the treatment  of anemia,  including the relief  of associated  signs 
and symptoms of anemia and reduced risk of blood transfusion. 
Similar to the Phase 3 dialysis studies, dose adjustment algorithm will be used to titrate roxadustat 
doses based on current Hb levels and the rate of change of Hb levels. Roxadustat doses may be held 
and/or the use of therapeutic  phlebotomy is allowed  in the event  of Hb excursions above the intended 
target range. Adverse events (AEs) and serious adverse events (SAEs), and laboratory parameters including electrolytes, liver enzymes, and iron indices, will be closely monitored to ensure the safety 
of treatment with roxadustat.  
In all three pi[INVESTIGATOR_464449], roxadustat was non-inferior and superior to epoetin alfa in the 
primary  efficacy  endpoint of the mean  change in  Hb from  baseline averaged  over Weeks  28-52. The 
efficacy of roxadustat, achieved with less IV iron supplementation, is accompanied by [CONTACT_464469], and demonstrated effective erythropoiesis regardless of inflammation with sustained response with stable mean roxadustat doses over  time. In these dialysis studies, roxadustat 
treatment has shown a 14% reduction in MACE+ risk compared to epoetin alfa, and the risk of MACE  and ACM in  roxadustat treated  patie nts are  non- inferior to  those treated  with  epoetin  alfa.  In 
incident dialysis  patients,  roxadustat treated  patients  had a 30% reduction in the risk of MACE  and a 
34% reduction in MACE+, with a trend towards lower ACM risk, in comparison to epoetin alfa.  
The safety  of treatment with roxadustat will be carefully  monitored by [CONTACT_513352]. Based  on data so far obtained, 
treatment with roxadustat is expected to be efficacious in treat ing anemia in patients with CKD.  
The safety profile of the compound, together with the safety monitoring implemented would minimize  the risk to study  participants.  The benefit -risk in this study is therefore  deemed  acceptable.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  30 of 74  
 3. OBJECTIVES AND ENDPOINTS  
3.1. Objectives  
3.1.1. Primary  Objectives  
To confirm safe and effective Roxadustat dosing regimens among chronic dialysis subjects 
converted  from  ESA  therapy  (>=6  weeks  ESA  treatment)  or who are ESA -naïve (<6 weeks  ESA 
treatment).  
 
3.1.2. Safety/Exploratory Objectives  
• Assessment  of treatment -emergent  adverse events  (TEAEs)  and serious adverse events 
(TESAEs)  
• Laboratory parameters,  including iron indices  
• Utilization  of intravenous (IV) iron 
• To test operational characteristics  of converting a population of ESRD  subjects  from  an 
injectable to oral anemia therapy  
 
3.2. Efficacy Endpoints  
3.2.1. Efficacy  Endpoints:  
• P roportion of subjects  with mean  Hb > 10g/dL, averaged  from  Week  16-through Week  24 
• Mean  Hb change from  baseline to  average Hb  from  Week  16-Week  24 
3.2.2. Exploratory Endpoints/Analyses  
The additional exploratory endpoints in this study are: 
• Time  to first RBC transfusion  
• Proportion of patient  with a mean  Hb levels  ≥10 g/dL in the first 9 weeks  after conversion  
• Proportion of patient  with a mean  Hb level  ≥10 g/dL based  on baseline ESA  use status  (≥ 
6 weeks  and < 6 weeks)  
• Evaluate the utilization  of intravenous (IV)  iron (IV iron use/4  weeks)  
• Evaluate the effect  on iron indices  
• Evaluate dosing adherence 
• Conversion subjects:  
− Comparison of starting  dose of roxadustat to roxadustat dose at Week  16-24 
• Mean  number of dose adjustments during study  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  31 of 74  
 3.3. Safety Endpoints  
Study- specific safety  will be assessed  by [CONTACT_2889]:  
• Incidence of treatment  emergent  adverse  events  (TEAEs)  and treatment  emergent  serious 
adverse events (TESAEs)  
• Clinically  significant changes  in laboratory values  from  baseline  
• Vital signs  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664673] 
subjects receiving chronic dialysis either after conversion from a stable ESA dose: ESA use > 6 
weeks  prior to conversion to roxadustat dosing or as initial anemi a treatment,  in subjects  with < 6 
weeks of total ESA use prior to start of roxadustat dosing. 
The study periods are: 
• Screening  Period: Up to 6 weeks  
• Treatment  Period: 24 weeks  
• Post- Treatment  Follow- Up Period: Subjects  permanently  discontinuing roxadustat, should 
have one final safety assessment (TEAEs and TESAEs) [ADDRESS_664674]. 
Figure 2: Study Design  Overview  
 
 
Guidelines for patients  receiving  home- dialysis:  
Home -dialysis  patients  are allowed  to participate  in this study. Investigators may use delivery 
services for medication dispense and/or local laboratory blood draw and/or testing 
For home- dialysis  patients,  investigators may adjust study visit frequency  and method of visits  such 
as use of telemedicine including dose-dispensation schedule in consideration of clinical 
circumstances and convenience of the patient.  
To simplify the study procedures for home-dialysis patients, renal ultrasound can be exempted, 
Screening Visit and Day [ADDRESS_664675] 
visit research -center during Screening/Day 1, and Week 24 (or if discontinued prematurely) and 
clinical  laboratory testing  for these  visits  need  to be sent to the central  lab. For other visits  (per SOA), 
investigator/authorized study staff should contact [CONTACT_513353], such as phone (audio, video call etc.) to collect study related information e.g. documentation of study drug dose, hemoglobin level, adverse events including hospi[INVESTIGATOR_059], conmed changes, transfusion etc, and to provide instructions on study drug dose adjustments. When possible, investigator should make 

DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664676] of care visits to the clinic with the study visit that falls around that time 
frame  (out of window protocol deviation will be exempted)  in order to perform  in-center  assessments, 
central laboratory draws as deemed necessary by  [CONTACT_513345].  
Hemoglobin levels every 2 to 4 weeks (as part of CBC listed in SOA) are needed for dose 
adjustments of roxadustat. The hemoglobin testing between Weeks [ADDRESS_664677] results need to be made available to the study file.  
Combining Screeni ng and Day  1 visits:  
Laboratory values related to eligibility assessments (e.g. LFTs, Hepatitis B and C, HIV, serum 
pregnancy, CBC/Hb, iron parameters) performed at a local lab within 12 weeks prior to 
enrollment/Day  1 may be used instead  of central  laboratory values  (done during screening)  to confirm 
eligibility,  if available.  If local  laboratory values  are not available,  Screening  and Day [ADDRESS_664678] considering the current clinical condition and convenience of the patient. Upon reviewing central lab values collected at Day 1, PI [INVESTIGATOR_513336] (e.g. very high LFT values). 
 
4.2. Study  Rationale  
The roxadustat phase 3 program  provided minimal data  about conversion of subjects from  CERA  to 
roxadustat. The  purpose of this  trial is  to enhance  the understanding of safe  and effective conversion 
from CERA to roxadustat in a population of patients receiving chronic dialysis. 
 
4.3. Screening  Period  
After  signing the informed  consent, subjects  enter  the Screening  Period. All screening  procedures are 
to be completed within 6 weeks. Subjects will be evaluated per the protocol inclusion/exclusion criteria to determine eligibility for participation in this trial.  
 
4.4. Treatment Period  
At the Day 1, subjects  will have had discontinued prior prescription of CERA  therapy  for 2 weeks 
and will initiate roxadustat therapy.  
 
4.5. Starting Dose  of Study  Drug  
4.5.1. Route  of Administration  
Oral (all tablets  must be administered  whole)  
 
4.5.2. Dosing  Frequency  
Subjects will be dosed three times weekly (TIW), except if a subject requires < 60 mg/week to 
maintain  Hb levels,  in which  case dose frequency  may be reduced  in a stepwise  fashion, e.g., to twice 
weekly (BIW), then once weekly (QW). 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  34 of 74  
 4.5.3. Initial Doses  
 
[IP_ADDRESS]. Conversion from  CERA to Roxadustat:  
The in itial roxadustat dose is determined  using a conversion table  based  on the subject’s  previous 
prescribed CERA dose in the last 8 weeks prior to enrollment ( Table 1).  
Roxadustat treatment  should start two weeks  after stoppi[INVESTIGATOR_513337].  
If the converted  initial dose exceeds  the maximum dose of 3.0 mg/kg/dose then the next- lower  dose 
step should be chosen as the initial dose. 
Table 1: Conversion from  CERA  to Roxadustat  
 
 
Previous  Dose  of 
Mircera® 
(mcg/month)  Starting Dose of 
Roxadustat (mg/dose 
TIW)  
<80 70 
80 to 120 100 
121 to 200 150 
>200  200 
 
 
[IP_ADDRESS]. Initiation  of Roxadustat Dosing  in subjects  with  < 6 weeks  of prior CERA or no prior 
ESA use:  
The initial roxadustat dosing is based  on broad body weight categories  (estimated  dry weight at 
enrollment) as described in Table 2. Table 2: Initial Roxadustat Dosing:  
 
 
 
Body Weight Category  < 100 kg  ≥ 100 kg  
Roxadustat Dose  (TIW)  70 mg  100 mg  
Note:  Weight  in HD subjects  = subject’s  estimated  dry weight  at enrollment. 
 
[IP_ADDRESS]. Dose  Adjustments:  
Dose  adjustment evaluations will be made every  4 weeks  and doses will be titrated  based  on Hb level 
and rate of Hb change according to Appendix 1. Any potential dose escalation/dose reduction will be 
at pre- defined dose step increments.  
A dose reduction may be implemented  at any time if the following criteria  are met:  
• Rate of Hb rise > 2 g/dL within  4 weeks:  reduce dose by 1 dose step  
• Hb level  > 13g/dL: hold dose, until Hb  drops to  < 12g/dL, resume dosing at 2 dose steps 
lower  
Any dos e adjustment will reset  the dose-adjustment window to  every  4 weeks  thereafter  (e.g., dose 
adjustment for a qualified reason at Week 6 leads to next dose adjustment at Week 10). 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664679] not exceed  the maximum allowable dose of 3.0 mg/kg/dose or [ADDRESS_664680]-Treatment Follow- Up Period  
After completing the Treatment Period (Week 24/EOT) , subjects who wish to permanently 
discontinue roxadustat and switch  to an ESA,  the first ESA  dose should be administered  at least two 
days after the last roxadustat dose.  
Subjects  permanently  discontinuing roxadustat (at Week  24 or early  termination),  should have one 
final safety assessment [ADDRESS_664681] roxadustat dose.  
 
4.7. Concomitant  Medications,  Procedures  and Nondrug  Therapi[INVESTIGATOR_014]  
4.7.1. Concomitant Medications  
Concomitant medications  are any prescription  or over-the-counter preparations,  including herbal 
products and “natural remedies”, used by a subject while participating in this clinical study. 
For all concomitant med ication use, an indication for its use should be provided. If the stated 
indication  is a nonspecific condition (e.g., “rash”),  documentation of the condition, as specific as 
possible, should be maintained in the subject’s clinical study records as source documentation. 
Use of herbal medicine  during the study is  not prohibited but strongly discouraged. All  herbal and 
natural  remedies  should be reviewed  by [CONTACT_513354], may be allowed  to 
continue at the same dose.  
 
[IP_ADDRESS]. Phosphate  Binders  
When coadministered with roxadustat, in a clinical pharmacology study, the bioavailability of 
roxadustat was reduced. Subjects should be advised to discuss with the Investigator when changing 
the dose or dosing time  of their phosphate binder while  taking roxadustat. To optimize  the absorption 
of roxadustat, subjects  should be advised  that roxadustat be taken  at least one hour before or one hour 
after their phosphate binder. This does not apply to Lanthanum. 
 
[IP_ADDRESS]. CYP2C8  and UGT1A9  Modifiers  
Titrate  the dose of r oxadustat  based  on monitoring of Hb levels  when  initiating  or discontinuing 
concomitant treatment with inducers or inhibitors of CYP2C8, or inhibitors of UGT1A9. 
 
[IP_ADDRESS]. Statins  
When coadministered with roxadustat, in clinical pharmacolgical studies, hydroxymethylglutaryl 
co
enzyme A reductase inhibitor (statin) exposure was increased [ADDRESS_664682]  of ethnicity,  other concomitant medications, 
renal and hepatic function. Goals of lipid lowering treatment should be maintained as clinically indicated. The dose of statins should not exceed the recommended daily dose in Table 3.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  36 of 74  
 Table 3: Recommended  Maximum Daily  Dose  of Statins  
 
Statins  Recommended  maximum  dose  (mg/day)  
Atorvastatin  [ADDRESS_664683]-line iron supplementation. Subjects randomized to roxadustat had a reduced need of IV iron 
compared to the active ESA comparator.  
In this study, oral iron may be administered.  Dose  and frequency  of administration  are to be 
determined by [CONTACT_093]. 
 
[IP_ADDRESS]. Oral  Iron  Supplementation 
In this study, oral iron may be administered  for iron supplementation without restriction.  Dose  and 
frequency of administration of oral iron are to be determined by [CONTACT_093]. 
 
[IP_ADDRESS]. Intravenous (IV) Iron  Supplementation  
Intravenous iron should be considered  for subjects with ferritin  < 200ng/mL or TSAT  <20%.  
In addition to scheduled  assessments (Appendix 2 ), iron indices  may be assessed  anytime  (via central 
lab) to evaluate iron storage status of the subjects, if considered necessary by [CONTACT_737]. 
 
4.7.3. Rescue Therapy  Guidelines  
Rescue therapy guidelines are provided to optimize the standardization of rescue therapy by 
[CONTACT_513355].  Use of rescue therapy  and reason 
for rescue therapy should be recorded in the electronic case report form (eCRF).  
 
[IP_ADDRESS]. Red Blood Cell Transfusion (all subjects)  
RBC transfusion should be considered if rapid correction of anemia is required to stabilize the 
subject’s condition (e.g., acute hemorrhage) or the Investigator is of the opi[INVESTIGATOR_167384] a medical  necessity.  If the situation  permits,  the Medical  Monitor should be informed 
prior to any scheduled RBC transfusion. Study treatment may continue during or after the RBC transfusion.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  37 of 74  
 [IP_ADDRESS]. Erythropoiesis  Stimulating  Agents  
If possible, the use of ESAs as a “Rescue” modality should be carefully considered, and should be 
restricted  to no more than one cycle of use during the Treatment  Period; the Investigator may initiate 
use of an approved erythropoietin (EPO) analogue if all of the following criteria are met: 
• A subject’s  Hb level  has not sufficiently  responded to two or more  dose increases  or the 
maximum dose of study drug has been reached, and 
• The subject’s  Hb is < 8.5 g/dL on two consecutive measurements  at least five days apart; 
and 
• Clinical judgment does not suggest iron deficiency  or bleeding as a cause of lack of 
response or rapid decline in Hb, and 
• Reducing the risk of alloimmunization  in transplant  eligible  subjects  and/or reduction of 
other RBC transfusion- related risks is a goal  
Such  ESA  Rescue should be started  ≥ [ADDRESS_664684] dose of roxadustat. 
ESA Rescue should be stopped when Hb > 9 g/dL or after 4- weeks, whichever comes first. If a 
subject  requires  longer than 4-weeks  therapy  due to inadequate response, or in other extenuating 
circumstances, the Medical Monitor should be contact[INVESTIGATOR_530].  
Study treatment  should be resumed  after the following  intervals:  
• Two days after stoppi[INVESTIGATOR_167385]  
• One week  after stoppi[INVESTIGATOR_167386] 
• Two weeks  after stoppi[INVESTIGATOR_167387]- epoetin  beta (Mircera®) 
If more  than one cycle of ESA  rescue is required, the Investigator should permanently discontinue 
study drug. 
Inadvertent  ESA  administration,  such as ESA  administration  during a hospi[INVESTIGATOR_059],  should not be 
counted as  rescue unless above criteria  are met; these subjects  may  be allowed  to restart  Roxadustat 
dosing if considered safe by [CONTACT_47998]. 
All E SAs  used during the Treatment  Period, either  planned or inadvertent,  should be recorded. 
ESAs and Roxadustat should not be administered concomitantly. 
[IP_ADDRESS]. Emergency  Procedure (Therapeutic Phlebotomy)  
If there are clinical  concerns for a subject’s  high Hb levels,  the Investigator may  decide to perform  a 
therapeutic phlebotomy in addition to temporarily withholding the study drug. This should be 
documented and discussed with the Medical Monitor. 
 
4.7.4. Prohibited  Medications/Therapi[INVESTIGATOR_014]/Substances  
The following medications/therapi[INVESTIGATOR_464450]:  
• Any investigational drug from  4 weeks  prior to  screening  until EOS 
• Androgens from  screening  until EOS 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  38 of 74  
 • Iron-chelating  agents  (e.g., deferoxamine/desferrioxamine,  deferiprone, or deferasirox 
therapy) from 4 weeks prior to enrollment until EOS 
• Dapsone (at any dose) from  screening  until EOS 
• Chronic doses acetaminophen/paracetamol  > 2.0 g/day  from  enrollment until [ADDRESS_664685] agree to 
practice a dual method of contraception, for example, a combination of the following: (1) oral 
contraceptive, depo progesterone, or intrauterine device; and (2) a barrier method (condom or diaphragm). Male subjects (nonsurgically sterile; i.e., no vasectomy) with female partners of childbearing potential who are not on birth control must agree to use a barrier method of contraception (e.g., condom) or the female partner  must agree to use contraception as described  above 
unless practicing complete sexual abstinence.  
Subjects must agree to practice above contraceptive methods, as applicable, for the entire duration of the study, from enrollment through the EOS visit. It is highly recommended that they continue to practice  the contraceptive methods for [ADDRESS_664686] will be 
established  through demographics, medical  history, clinical  laboratory  values,  vital signs, physical 
examination (PE) During the course of the study, vital signs, PE, and laboratory tests will be performed at regular intervals as described in schedule of assessments ( Appendix 2) . 
Any significant findings prior to administration of study drug will be considered as baseline conditions and if appropriate, will be captured as baseline medical history. Any clinically significant (CS) changes  from  baseline will be monitored throughout the study and appropriate interventio ns will 
be taken accordingly. Clinical laboratory tests may be assessed at additional times on unscheduled visits for safety reasons. 
All adverse events,  SAEs,  and ongoing concomitant medication  usage will be monitored and recorded 
throughout the treatment and post- treatment follow -up periods. Serious adverse event reports will be 
evaluated individually to assess the impact of the event, if any, on the overall safety of the product 
and on the study itself. Cumulative AEs will be monitored. Serious adverse events and AEs will be followed until resolved, or deemed stable. See Section 8 for details on AE and SAE reporting. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664687]  is eligible  for the study if all of the following  criteria  are met:  
1. Subject  has been  informed  of the investigational nature of this study and has given written 
informed consent in accordance with institutional, local, and national guidelines 
2. Subject  is ≥ 18 years of  age 
3. Receiving  chronic dialysis for end stage renal  disease  (ESRD)  
4. Prior ESA  use: 
• Fo r  a subject  converting from  a ESA : On CERA  ≥6 weeks  and the prescribed  CERA  dose 
remain stable (as determined by [CONTACT_976]) during the 4 weeks prior to initiating roxadustat 
treatment.  
• Subject  is in itiating  anemia treatment: Defined  as: < [ADDRESS_664688] be a functioning native arteriovenous fistula  or graft  with adequate flow 
in the opi[INVESTIGATOR_871], or permanent tunneled catheter.  
6. Screening  Hb (based  on central  lab value;  measured  within  10 days prior to initiating 
roxadustat treatment):  
• S ubjects  converting from  an ESA : screening  Hb is between  9.0 to 12.0 g/dL 
• Subjects  initiating  anemia treatment: screening  Hb is < 10.0 g/dL 
7. Ferritin  ≥ 50 ng/mL, Transferrin  saturation  (TSAT)  ≥ 10% at screening  (subject  may qualify 
after receiving iron supplement per local standard of care) 
8. Subject’s alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are ≤ 3 x upper limit of normal (ULN),  and total bilirubin  (TBL)  is ≤ 1.[ADDRESS_664689] and ALT are within normal limit)  
9. Subject’s  body weight (estimated  dry weight in HD subjects)  is 45.0 to 160.0 kg 
 
5.2. Exclusion  Criteria  
Subjects  will be excluded  if any of the following criteria  are met: 
1. Subject  has received  a red blood cell (RBC)  transfusion within  [ADDRESS_664690]  has a known hereditary  hematologic disease such as thalassemia  or sickle  cell anemia, 
pure red cell aplasia or other known causes for anemia other than chronic kidney disease 
(CKD)  
4. Subject  has known hemosiderosis, hemochromatosis, coagulation disorder, or 
hypercoagulable condition 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664691]  has a known chronic inflammatory  disease  that is determined  by [CONTACT_513356] (e.g., systemic lupus erythematosus, rheumatoid arthritis, celiac 
disease)  
6. Subject  is anticipated  to undergo elective  surgery  that is expected  to lead to significant blood 
loss during the study period or anticipated elective coronary revascularization. 
7. Subject  has active or chronic gastrointestinal bleeding 
8. Subject  has been  treated  with iron-chelating  agents  within  [ADDRESS_664692]  has a history of chronic liver disease  (e.g., chronic infectious hepatitis,  chronic auto- 
immune liver disease, cirrhosis, or fibrosis of the liver) 
10. Subject  with New  York  Heart  Association  (NYHA)  Class  III or IV congestive heart  failure  
11. Subject has had an MI, acute coronary syndrome, stroke, seizure, or a thrombotic/thr omboembolic event  (excluding vascular  dialysis  access  stenosis/thrombosis) 
(e.g., DVT or pulmonary embolism) within [ADDRESS_664693]  has a diagnosis or suspi[INVESTIGATOR_2798] (e.g., complex kidney cyst or Bosniak Category  II or 
higher) of renal cell carcinoma (PI’s discretion)  
14. Subject  has a history of malignancy, except  for the following: cancers  determined  to be cured 
or in remission for ≥ [ADDRESS_664694]  is positive for any of the following:  
• Human  immunodeficiency  virus (HIV)  
• Hepatitis  B surface  antigen  (HBsAg)  
• Anti-hepatitis  C virus antibody (anti-HCV Ab) 
16. Subject  has an active clinically  significant infection  at the time of enrollment as determined 
by [CONTACT_093] 
17. S
ubject has any of the following known untreated conditions as determined by [CONTACT_1275]: proliferative  diabetic  retinopathy, diabetic  macular  edema,  macular  degeneration 
or retinal vein occlusion (subjects who are already blind may qualify to participate)  
18. Subjects  with prior organ transplant who have one of the following conditions or states  
19. a) Experienced rejection  of transplanted  organ within  6 months of transplantation  
20. b) Currently  on high doses of immunosuppressive therapy  (per discretion  of the investigator)  
21. c) Are scheduled  for organ  transplantation  (on the waiting  list for kidney transplant is not 
exclusionary)  
22. Subject  has participated  in an interventional clinical  study or has been  treated  with an 
investigational drug within [ADDRESS_664695] has drug-treated gastroparesis, short-bowel syndrome, or any other gastrointestinal condition that may lead to reduced  absorption of study drug (determined  by [CONTACT_093]) 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664696]  has an anticipated  use of dapsone or androgen in any dose amount or anticipated 
chronic use of acetaminophen or paracetamol > 2.0 g/day during the study 
25. Subject  has a history of alcohol or drug abuse within  6 months prior to screening  as 
determined by [CONTACT_464457] 
26. Females of childbearing potential, if not practicing complete sexual abstinence or using 
contracep tion as detailed in the protocol; male subjects (if not surgically sterile; i.e., no 
vasectomy)  with sexual  partners  of childbearing potential,  if not practicing  complete  sexual 
abstinence or using contraception 
27. Pregnant or breastfeeding females  
28. Subject  has any medical  condition that in the opi[INVESTIGATOR_513338] a safety 
risk to the subject  in this study, which  may  confound efficacy  or safety  assessment,  or may 
interfere with study participation  
 
5.3. Subject  Discontinuation  and Withdrawal  
The subject  is free to permanently discontinue study medication  at any time,  without prejudice to 
further treatment.  Discontinuation  from  study medication  is not the same as  complete  withdrawal 
from the study (i.e., withdrawal of consent). 
Subjects  may  withdraw consent and  discontinue from  the study at  any time  by [CONTACT_513357]-up without any prejudice. 
A subject who decides to discontinue study medication will always be asked about the reason(s) to 
discontinue study medication and the presence of AEs (if any). These data will be ascertained and 
documented by [CONTACT_513358].  Any subject  discontinuing 
study medicatio n will be followed up for 28 days after discontinuing study medication whenever 
feasible for purposes of adverse event reporting. 
Reasons  for permanent discontinuation of study medication:  
• Subject’s  decision  (subject no longer wants  to continue study medication  (i.e., withdrawal 
of consent) 
• Investigator’s decision that it is in the best interest  of the subject  to be withdrawn  from  the 
study  
• A dverse events  
• Significant noncompliance with study procedures, as determined  by [CONTACT_167424]  
• Lack  of efficacy  / Meets  ESA  withdrawal  criteria  
• Subject  is lost to follow- up 
• Subject  got transferred  to a different  location/dialysis  center  
• Subject  is no longer requiring dialysis  due to kidney transplant  
• Site terminated  by [CONTACT_456]  
• Pregnancy  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  42 of 74  
 • Death  
Upon discontinuation from the study, both female subjects of childbearing potential and male 
subjects  with partners  of childbearing potential must continue to use a medically  acceptable method 
of contraception for [ADDRESS_664697] study drug administration.  
5.4. Replacement  of Subjects  
Subjects  will not be replaced  from  this study. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664698]  
6.1. Formulation  
Roxadustat is supplied by [CONTACT_2918], Inc.  as red coated,  tablets  for oral administration,  in strengths of 
20 mg, 50 mg, 70 mg100 mg and 150 mg. The excipi[INVESTIGATOR_270130], 
microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, and colorant Red Opadry II. All ingredients used for manufacture of roxadustat comply with US and European Union compendia or regulatory standards. Strengths are different in size and debossing reflects the strength (i.e., 20, 50, 70 100 or 150 mg). Due to the light-sensitive nature of roxadustat and to minimize exposure of the active pharmaceutical ingredi ent to light, tablets should remain in the original 
packaging for as long as possible and be administered as intact tablets only. 
 
6.2. Storage  
Roxadustat tablets  should be protected  from  light,  and stored  at room temperature between  15°C  and 
30°C (59ºF to 86ºF ). 
Study drug should be stored  in a securely  locked  area to which  access  is limited  to appropriately 
authorized study personnel. 
 
6.3. Study  Drug  Handling  and Disposal  
Study drug and packaging provided by [CONTACT_464475]. Upon completion of the study or termination of the investigational site, all used, unused, and partially  used  study drugs; and all study drugs that were not 
dispensed will be shipped to a site designated by [CONTACT_167426]/institutional policies by [CONTACT_22269]/authorized staff after drug accountability and reconciliation has been completed by [CONTACT_2728]. 
Please refer  to the Study Reference Manual  or Pharmacy  Manual  for additional information.  
 
6.4. Route  of Administration  and Dose  
Route  of Administration:  Oral (all tablets  must be administered  whole)  
Dosing  Frequency:  Subjects  will be dosed three times  weekly  (TIW),  except if a subject  requires  < 
60 mg/week to maintain Hb levels, in which case dose frequency may be reduced in a stepwise 
fashion, e.g., to twice weekly (BIW), then once weekly (QW), then every-2- weekly (Q2W), etc.  
The first dose of roxadustat should be administered on Day [ADDRESS_664699] one hour before or one hour after the phosphate binder. 
6.5. Overdose,  Emergency  Procedures  and Management  of Overdose  
The maximum allowed  roxadustat dose is 400 mg or 3.0 mg/kg/dose, whichever  is lower.  Any dosing 
exceeding the maximum allowed roxadustat dose should be reported within 24 hours. The Medical 
Monitor should be contact[CONTACT_112073]. Symptoms associated with overdosing, if any, will be reported as adverse events.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664700]  should receive supportive care and 
monitoring. The Sponsor’s Medical Monitor should be contact[CONTACT_77792].  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  45 of 74  
 7. STUDY  PROCEDURES  
7.1. Study  Procedures  by [CONTACT_4838]  / Schedule  of Assessments  
During study visits,  unless otherwise indicated,  it is preferred  that all assessments  including labs and 
physical examinations should be completed prior to dialysis. For subjects on home- dialysis please 
also see guidelines in Section 4.1. 
Table 4: Schedule  of Assessments  
 
Visit  / Week:  Screening 
Visit  Day 1 Wk 2 to 8 
(Every  2 weeks  
± 4 days)  Wk 12 to24 f 
(Every  4 weeks  
± 4 days)  Post-Treatment  d 
Follow -up 
± 7 days  
Written  informed  consent  X     
Eligibility  criteria  X X    
Demographics  and medical  history  X     
Height,  weight  (estimated  dry 
weight)  X X a    
Blood  pressure,  heart  rate, 
temperature  X X X X X 
Physical  Exam  X   X f  
Hemoglobin  (central  and local)  X c  X e X e X c 
CBC  with WBC  differential  X X Wks 4, [ADDRESS_664701] X b  Wk 8 Wks 16, 24 X 
Dose  adjustment    X X  
AE/CM  recording  X X X X X 
Study  drug dispensing   X X X  
 
 
Ab = antibody; CBC = complete blood count; CHr = reticulocyte  hemoglobin content; ELISA  = enzyme- 
linked immunosorbent assay; ET = early termination; HBsAg = hepatitis B surface antigen; hCG = 
human chorionic  gonadotropin; HCV = hepatitis  C virus;  HIV = human  immunodeficiency virus;  LFTs  
= liver function tests TIBC = total iron binding capacity; TSAT = transferrin saturation; WBC =white 
blood cells; Wk(s) = week(s); 
a Weight  only 
b Collect from  female subjects of child  bearing potential  only 
c Central labs only  
d [ADDRESS_664702] a separate central  Hb only when  CBC is not collected 
f Week 24 = EOT 
 
7.2. Screening  Period  
• Signed written  informed  consent  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  46 of 74  
 • Inclusion/Exclusion criteria  verification  
• Demographics and medical  history  
• Height and weight (estimated  dry weight)  
• Vital signs (BP, HR, temperature)  
• Physical  Examination: HEENT,  respi[INVESTIGATOR_696], cardiovascular,  abdomen, extremities,  and 
neurological parameters 
• Laboratory tests:  
− Hemoglobin (central)  
− Complete  blood count (CBC)  with WBC  differential  
− Serum  chemistry  
− CPK  
− Serum  iron, ferritin,  total iron-binding capacity  (TIBC),  transferrin  saturation  (TSAT), 
Reticulocyte count and hemoglobin in reticulocytes (CHr) 
− Enzyme-linked immunosorbent assay  (ELISA)  for HIV 
− Hepatitis  B surface  antigen  (HBsAg)  
− Anti-HCV Ab 
− Serum  hCG pregnancy  test 
• Renal  ultrasound or other imaging  may be performed  during screening  to rule out renal 
cell carcinoma or suspi[INVESTIGATOR_513339].  
• Review  and record  concomitant  medications  
• Review  and record  procedures and  nondrug therapi[INVESTIGATOR_014]  
• Review  and record  AEs,  if any (capture the event  under medical  history, if applicable)  
7.2.1.  Additional  Screening  Assessments  
If a subject’s laboratory results  do not meet  eligibility  criteria  at Screening, specific laboratory 
assessments may be repeated within the Screening Period.  
If a subject fails screening, he/she may be re-screened  once deemed  appropriate by [CONTACT_093]. 
Where possible, an approval should be obtained from the Medical Monitor prior to re-screening. 
 
7.3. Treatment Period  
The Treatment  Period  begins on the first day of dosing with study treatment  (Day  1). 
 
7.3.1. Day [ADDRESS_664703] dose of study drug 
• Inclusion/Exclusion criteria  verification  
• Vital signs (BP, HR, temperature)  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  47 of 74  
 • Estimated  dry weight  
• Local  Hb assessment  
• Laboratory tests:  
− Complete  blood count (CBC)  with WBC  differential  
− Serum  chemistry  
− CPK  
− Serum  iron, ferritin,  total iron-binding capacity  (TIBC),  transferrin  saturation  (TSAT), 
Reticulocyte count and hemoglobin in reticulocytes (CHr) 
− Hemoglobin local  
− AE/CM  recording  
− Study drug administration  
7.3.2. Weeks  2 to 8 (Every  2 Weeks,  ±4 days)  
• Vital signs (BP, HR, temperature)  
• Laboratory tests:  
− Hemoglobin (central  and local  lab) 
 Draw  a central  Hb only on visits  CBC  is not collected  
• Week  4 and Week 8:  
− Complete  blood count (CBC)  with WBC  differential  
− Serum  chemistry  
• Week  8: 
− CPK  
− Serum  iron, ferritin,  total iron-binding capacity  (TIBC),  transferrin  saturation  (TSAT), 
Reticulocyte count and hemoglobin in reticulocytes (CHr) 
− Serum  hCG pregnancy test 
• Dose  review  at every  visit and dose adjustment every  4 weeks  
• TEAE/CM  recording  
• Study drug dispensing  
7.3.3. Weeks  12 to 24 (Every  4 weeks,  ±4 days)  
• Vital signs (BP, HR, temperature)  
• Physical  Examination: HEENT,  respi[INVESTIGATOR_696], cardiovascular,  abdomen, extremities,  and 
neurological parameters (at EOT/Week 24 only) 
• Hemoglobin (central  as part of CBC and  local  lab) 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  48 of 74  
 • Week  16 and Week  24: 
− Complete  blood count (CBC)  with WBC  differential  
− Serum  chemistry  
− CPK  
− Serum  iron, ferritin,  total iron-binding capacity  (TIBC),  transferrin  saturation  (TSAT), 
Reticulocyte count and hemoglobin in reticulocytes (CHr) 
− Serum  hCG pregnancy  test (female of child  bearing  potential only)  
• Dose  adjustment  
• AE/CM  recording  
• Study drug dispensing  
Week  24 visit is considered  as End of Treatment  (EOT)  visit 
Subjects  permanently  discontinuing roxadustat before Week  [ADDRESS_664704]  Early  Termination  visit 
(same as Week 24/EOT visit) as soon as possible. 
 
7.4. Post-Treatment Follow-up  visit (for subjects  discontinuing  roxadustat 
treatment at Week 24 or Early Termination) (±7 days)  
• Final  safety  assessment  [ADDRESS_664705] roxadustat dose.  
• Vital signs (BP, HR, temperature)  
• Laboratory tests:  
− Complete  blood count (CBC)  with WBC  differential  
− Serum  chemistry  
− Serum  hCG pregnancy  test (female of child  bearing  potential only)  
− AE/CM  recording  
Subjects  who wish  to permanently  discontinue roxadustat, should receive the first ESA  dose at least 
two days after the last roxadustat dose. 
An extension of roxadustat treatment  after [ADDRESS_664706]. 
 
 
7.5. Missed  Visits  
Every  attempt should be made to complete  all study visits  within  the visit window as outlined in the 
Schedule of Assessments.  
 
7.6. Unscheduled Visits  
Unscheduled visit(s)  and laboratory assessments  may be required  at the discretion  of the investigator. 
Please refer to the eCRF completion guidelines for additional information. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  49 of 74  
 7.7. Laboratory  Assessments  
Details  regarding  sample  collection,  preparation and transport can  be found in  the central  laboratory 
manual.  Importantly, dose adjustments per the dosing algorithm  will be made on results from  local  
Hb testing. 
 
7.8. Central  Laboratory  
The following labs will be evaluated  by a central  laboratory in accordance with  the SOA in Appendix 
2 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  50 of 74  
 Chemistry  Panel:  
Albumin 
Bicarbonate BUN  
Calcium Chloride 
Creatinine  
Creatine  phosphokinase 
Glucose  
Lactic  Acid  Dehydrogenase  
Liver  Function Tests
[ADDRESS_664707] 
GGT  
Magnesium Phosphorus Potassium 
Total protein  
Uric acid 
HIV  and viral  Hepatitis  Panel:  
Anti- HCV  Ab tests 
HBsAg  
HIV ELISA  CBC:  
Basophils 
Eosinophils  
Erythrocyte  count  (RBC) 
Hct 
Hb 
Leukocyte  count  (WBC) 
Lymphocytes  
Mean  corpuscular  volume 
Mean corpuscular Hb  
Mean  corpuscular  Hb concentration 
Monocytes  
Neutrophils  
Neutrophils,  immature  (banded) 
Platelets  
Serum  Iron  Profile  
Ferritin 
Iron 
TIBC 
UIBC 
TSAT  
Additional  Laboratory Analytes:  
Reticulocyte  count 
CHr 
Serum  hCG pregnancy  test (for women  of 
childbearing potential only) Table 5: Central  Laboratory Tests  
 
Abbreviations:  ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood 
urea nitrogen; CBC = complete blood count; CHr = reticulocyte hemoglobin content;; ELISA = enzyme -linked 
immunosorbent assay; GGT = gamma-glutamyl transferase; Hb = hemoglobin; HBsAg = hepatitis B surface 
antigen;  Hct = hematocrit;  HCV = hepatitis  C virus;  HIV = human  immunodeficiency  virus;  RBC = red blood cell; 
TIBC = total iron binding capacity; UIBC=unsaturated iron binding capacity TSAT = transferrin sat uration;  
WBC = white blood  cell. 
 
[ADDRESS_664708]  or ALT  ≥3xULN  and total bilirubin  ≥ 2xULN Please refer to 
Appendix 2 “Liver  Function Monitoring”.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664709] 
immediately (within 24 hours of becoming aware) report to the sponsor all SAEs, regardless of whether the Investigator believes they are related to the study drug. 
The definitions of an AE, suspected  adverse reaction,  adverse reaction,  and SAE  are described  below 
in accordance with the FDA  Final Rule Vol 75, No 188, September 29, 2010; Article 18 of Directive 
2001/20/EC of the European Parliament and of the Council of [ADDRESS_664710] medical  occurrence associated  with the use of a drug in humans, whether or 
not considered drug- related.  
An AE can be any unfavorable and unintended sign (e. g., an abnormal and clinically significant laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. This includes any occurrence that is new in onset or aggravated in severity 
or frequency from the BL condition, or abnormal results of diagnostic procedures, including 
laboratory test abnormalities. An AE can arise from any use of the drug (e.g.,, off-label use, use in combination with another drug) and from  any route of administration,  formulation, or dose, including 
an overdose. 
An AE includes medical  conditions, signs, and symptoms  not previously observed  in the subject  that 
emerge during the protocol-specified AE reporting period, including signs or symptoms associated 
with an underlying condition that were not present prior to the AE reporting period ( Section 8.3.1)  
 
8.2.2. Definition  of a Serious  Adverse Event  
An SAE  is any AE or suspected  adverse reaction  that results  in any of the following outcomes:  
• Death  
• A life-threatening  AE (i.e., if in the view  of the Investigator or sponsor, the subject  was at 
immediate risk of death at the time of the event). Life-threatening does not refer to an event which hypothetically might have caused death if it were more severe. 
• Inpatient  hospi[INVESTIGATOR_707]  
• A persistent  or significant incapacity  or substantial disruption of the ability  to conduct 
normal life functions 
• A c
ongenital anomaly  or birth  defect  
• A medically important event not meeting the above criteria, but which may jeopardize a patient  or may require  medical  or surgical  intervention to prevent one of the other criteria 
listed in this definition. Examples of such medical events include allergic bronchospasm 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664711] study visit, except for pregnancy reporting ( Section 8.3.6) . 
AEs (non- SAE)  reported  during screening  should be reviewed  and captured  under medical  history, if 
applicable.  
Adverse events will be followed until resolved, stable, or until the subject’s last study visit or lost to 
follow-up. If an AE is not resolved  or stabilized  at the subject’s  last visit,  it is up to the discretion  of 
the investigator and/or study Medical Monitor to determine if further monitoring of the event is warranted.  
Adverse events  collected  prior to dosing of study drug will be considered  “non -treatment  emergent” 
while those reported after the first dose of study drug and up to [ADDRESS_664712] dose of study drug will be considered “treatment emergent” and be assessed for relationship to study drug. If an 
AE starts on Day 1, the investigator must assess as to whether the AE started prior to or after the administration of study medication and record accordingly. 
 
8.3.2. Adverse Event  Eliciting/Reporting  
During the AE reporting period, study site personnel will query each subject/caregiver  at each visit to 
assess for any AEs occurring since the previous visit. All AEs will be collected in response to non- 
leading, general questions about the subject’s well-being and any possible changes from the baseline or previous visit. This does not preclude the site from collecting and recording any AEs reported by [CONTACT_423]/caregiver to site personnel at any other t ime. 
Whenever possible, AE diagnoses should be recorded rather than just the signs and symptoms, as 
determined by [CONTACT_167440]. New indications for medications started after informed consent is obtained until [ADDRESS_664713] dose of study drug will be recorded  as AEs;  recurrence 
or worsening of medical conditions will also be recorded as AEs. Abnormal, clinically significant laboratory results, and PE findings will be recorded as AEs if they are deemed by [CONTACT_513359].  
The following attributes  must be assigned  to each AE: 
• Description  (Investigator’s verbatim  term describing the event).  
• Dates  of onset and resolution  
• Severity  
• Relationship  to study drug 
• Outcome  
• Action  taken  regarding study drug (action  taken  by [CONTACT_978] [INVESTIGATOR_270106]) 
• O
ther  treatment  required  
• Determination  of “seriousness”  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  53 of 74  
 8.3.3. Assessing  Adverse Event  Severity  
The Investigator should use the National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE)  version 4.0. For terms  not specified  as part of NCI-CTCAE,  the following 
guidelines should be used to determine grade: 
• Grade 1, Mild : Asymptomatic  or mild symptoms  which  the subject  finds easily  tolerated. 
The event is of little concern to the subject and/or of little -or-no clinical significance; 
clinical or diagnostic observations only; intervention not indicated. 
• Grade 2, Moderate:  The subject  has enough discomfort to cause interference  with or 
change in some of their age -appropriate instrumental activities of daily living (e.g., 
preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, managing 
money); local or noninvasive intervention indicated. 
• Grade 3, Severe:  The subject  is incapacitated  and unable to work  or participate in many 
or all usual activities. The event is of definite concern to the subject and/or poses substantial risk to the subject’s health or well-being; Likely to require medical intervention and/or close follow-up, including but not limited to hospi[INVESTIGATOR_318]. 
• Grade 4, Life-threatening:  The subject  was at immediate  risk of death  from  the event  as 
it occurred.  
• Grade 5, Death  related  to AE. 
8.3.4. Assessing  Relationship to Study  Drug  
Most of the information about the safety of a drug prior to marketing comes from clinical trials; therefore,  AE reports  from  Investigators are critically  important.  Moreover,  appropriately deciding 
whether the AE meets the definition of a suspected adverse reaction is usually the most difficult determination, but it is critical to avoid the mis -categorization of the product’s safety profile. 
Default  re
porting  of individual events  as possibly related  is uninformative and does not meaningfully 
contribute to the development of the drug’s safety profile. 
The Investigator must provide an assessment of the relationship of the AE to study drug in 
accordance with the guidance below. Absence of an alternative cause would not normally be 
considered  enough evidence to assess an event  as possibly related  or related  to study drug. The 
following are examples of adverse events and their relationship to study drug: 
Related  ( Adverse Reaction):  
Any event  for which  there is evidence to conclude that  the study drug caused  the event.  
Possibly  R elated  (Suspected Adverse Reaction):  
A single occurrence of  an event  that is uncommon, but is  a typi[INVESTIGATOR_513340], such as anaphylaxis, rhabdomyolysis, Stevens -Johnson 
syndrome, etc. 
One or more occurrences  of an  event  that is not commonly  associated  with  drug exposure but is 
otherwise uncommon in the population exposed to the drug. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  54 of 74  
 Not Related:  
The event  represents  the underlying disease (e.g., disease- related  symptoms, dise ase progression) and 
the presentation of the event is typi[INVESTIGATOR_2855]. 
The event  represents  a comorbid condition present  at the time the subject  entered  the study that has 
not worsened. 
The event  represents  a known adverse reaction  associated  with a co-medication  received  by [CONTACT_213009].  
The event  is common for the study population (e.g., cardiovascular  events  in an elderly  population).  
The Investigator must provide an assessment of the relationship of the event to study drug, as this 
informatio n is very important to monitor the real-time safety of the study drug. However, as the 
manufacturer  of the study drug, FibroGen is responsible for reporting suspected  adverse reactions  and 
adverse reactions to Health Authorities. 
 
8.3.5. Reporting  Serious  Adverse Events  on the Serious  Adverse Event  Report  Form  
All SAEs  must be reported  immediately  to the Sponsor and/or its designated  safety  management 
vendor.  
To report an SAE, the Investigator must fax or email an SAE Report Form to the Sponsor’s designated  safety management vendor within [ADDRESS_664714] be submitted  in a timely  manner  as additional information  becomes  available.  
Full details  of the SAE  should also be recorded  on the medical  records  and in the CRF.  The following 
minimum information is required:  
• Subject  number, sex  and age 
• The date of  report  
• A description of the SAE  (event,  seriousness of the event)  
• Causal  relationship  to the study drug 
For each SAE observed, the Investigator should obtain all of the information available about the event, including (but not limited to): clinical course of the event, hospi[INVESTIGATOR_167401], hospi[INVESTIGATOR_167402], death  certificate,  appropriate laboratory findings (including autopsies and 
biopsy results), and clinical examinations (including radiological examinations and clinical consultations).  
The medical  
 monitor is available to discuss safety  issues if needed.  
 
[IP_ADDRESS]. Reporting  Serious  Adverse Events  to the Institutional  Review  Board / Independent 
Ethics Committee  
The Investigator is responsible for notifying his/her Institutional Review Board (IRB) or Ethics 
Committee  (EC) of SAEs  in accordance with local  regulations. Sponsor, or its safety  representative, 
will provide to the Investigator a copy of any expedited safety reports that it intends to file with a 
regulatory authority. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  55 of 74  
 [IP_ADDRESS]. Deaths  
For any death  occurring during the subject’s  study participation,  regardless  of attribution,  the 
Investigator will report  the death  within  24 hours to the Sponsor’s Medical  Monitor and  their 
designated safety management vendor on an SAE form. 
The Investigator should notify the Sponsor and their designated safety management vendor of any 
death  or other SAE  occurring after a subject  has discontinued or terminated  study participation  that 
may reasonably be related to the study. 
The Investigator must submit the SAE  Report Form  and complete  the appropriate CRF  page for the 
event that led to the subject’s death. 
When  reporting  a death,  the event  or condition that caused  or contributed to the fatal outcome should 
be recorded as the primary event term on the SAE Report Form. 
 
8.3.6. Pregnancies:  Reporting  and Follow- up 
A pregnancy in a female subject or a male subject’s female partner must be confirmed by [CONTACT_513360] β -HCG test(s). If pregnancy is suspected, study drug may need to be interrupted until 
pregnancy is ruled out. If a female subject or the female partner of a male subject becomes pregnant 
while the subject is receiving study treatment or within [ADDRESS_664715] be completed and submitted to the Sponsor (by [CONTACT_513361]) within  [ADDRESS_664716] be reported by [CONTACT_2953] a Pregnancy Outcome Report Form, which should be sent to the Sponsor and/or its designated safety management vendor within [ADDRESS_664717] should be defined  as an AE only if the abnormality 
meets one of the following criteria:  
• I
nduces  clinical  signs or symptoms  
• Requires  active intervention 
• Requires  interruption or discontinuation of study medication  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  56 of 74  
 • In the opi[INVESTIGATOR_689], the abnormality  is clinically  meaningful and 
significantly different from baseline.  
 
8.3.8. Disease  Progression  
Disease progression can be considered as a worsening of a subject’s condition attributable to the 
disease for which the in vestigational product is being studied. It may be an increase in  the severity  of 
the disease under study and/or increases in the symptoms of the disease. As anemia is the condition being investigated  in this study, worsening anemia should not be reported  as an AE unless the subject 
is hospi[INVESTIGATOR_513341]: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664718] error,  median, 
minimum, and maximum.  
Categorical  variables  will be reported  by [CONTACT_513362].  
Analyses  of the efficacy  data will be based  on the Full Analysis Set (FAS)  Population. 
Safety data will be summarized descriptively based on the Safety Population. 
Operational  characteristics  of the drug will be evaluated  qualitatively  and descriptively  
 
9.1. Sample  Size Determination  
Approximately 200 subjects  with anemia of CKD (either  with or without prior treatment  with an ESA 
before enrolment) and on hemodialysis are planned in this study. This number of subjects distributed 
across the specified number of sites is adequate to evaluate the primary st udy objective. 
Assuming the proportion of subjects  that maintain  Hb levels  ≥10g/dL  from  Weeks  [ADDRESS_664719] 
80%, with a sample size of 200, the study will be able to produce a two-sided 95% confidence interval (CI) with a width equal of 11.5%. 
 
9.2. Analysis  Sets 
The FAS set will consist of all subjects who signed informed consent, who were enrolled, and who 
provided baseline Hb  data and data for at least one post baseline Hb time point. The FAS set will be 
used for all efficacy endpoints. 
The Safety  analysis  set will include all enrolled  subjects  receiving  at least 1 dose of study treatment. 
The safety analysis set will be used for all safety endpoints and exposure to study treatment 
outcomes.  
 
9.3. Analysis of the Efficacy Endpoints  
The efficacy  endpoint will be evaluated  using the proportion (%) of subjects with mean  value of Hb 
measurements of Week 16 -Week 24 > 10g/dL. 
The 95% CI  of the response rate will be presented  based  on the exact  method of Clopper- Pearson.  
For the efficacy  analysis,  a multiple  imputation  (MI) method will be used. This will be implemented 
on the raw Hb values, then the Hb- relates endpoint summaries will be derived based  on the imputed 
data (algorithm as used for the previous phase 3 studies). For continuous endpoints, changes from baseline will be presented descriptively. Missing Hb values will be imputed using a multiple imputation procedure. 
Proportion of responders will be presented  descriptively  with count and percentages  and 95% 
confidence interval of the responder rate. 
Time  to response will be analyzed  using the Kaplan -Meier  method with KM curve plotted.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  58 of 74  
 9.4. Safety Analysis  
The Safety  analysis  will be performed  using the Safety  Analysis Set (SAF).  Safety  parameters  include 
AEs, SAEs, laboratory parameters and vital signs. 
The number and percentage of subjects  reporting  treatment -emergent  AEs (TEAEs)  and TESAEs  will 
be tabulated.  
Descriptive  statistics  will be presented  for laboratory  and vital signs.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664720]  ACCESS  TO SOURCE  DOCUMENTS  
Following site prequalification  and/or initiation  of the study site, periodic monitoring visits  and site 
closeout visits  will be made by [CONTACT_2954].  The investigator must provide direct  access 
to, and allocate sufficient space and time for, the monitor to inspect subject source records, eCRFs, 
queries, collection of local laboratory normal ranges (if applicable), investigational product accountability records, and regulatory documents in accordance with GCP and ICH E6 guideline. 
The purpose of study monitoring is  to verify  the following:  
• The rights and well-being  of human subjects are protected  
• The reported  data are accurate,  complete,  and verifiable  from  source documents  
• All data are collected,  tracked,  and submitted  by [CONTACT_167446],  including 
unscheduled and missed assessments  
• The reported  data are reconciled  across  all data sources  (e.g., laboratory, safety,  IWRS, 
clinical databases)  
• The conduct of the study is in compliance with the currently approved 
protocol/amendment(s), with GCP,  and with the applicable regulatory requirement(s)  
The investigator must also permit the  FDA  or other applicable regulatory authorities to inspect 
facilities  and records  pertaining  to this study if so requested.  If the investigator  is notified  of an 
inspection pertaining to this study by [CONTACT_167447], the investigator must notify Sponsor immediately. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664721] 
Operating Procedures by [CONTACT_464480](s), as appropriate, to ensure that this clinical study is conducted and data are generated,  documented (recorded) and reported  in compliance with 
the protocol, ICH E6 (GCP), and other applicable regulations. 
This study will be monitored by [CONTACT_464481], and may be audited 
or reviewed by [CONTACT_494586], IRB/IEC, and/or regulatory authorities.  This implies that monitors and auditors/inspectors will have the right to  inspect the study 
sites at any time during and/or after completion  of the study and will have direct  access  to data/source 
documents, including the subject's file. By [CONTACT_4907], Investigators agree to this requirement.  
The purpose of trial monitoring is  to verify  the following:  
• The rights and well-being  of human subjects are protected.  
• The reported  data are accurate,  complete,  and verifiable  from  source documents.  
• All data are collected,  tracked,  and submitted  by [CONTACT_464483], 
including unscheduled and missed assessments 
• The reported  data are reconciled  across  all data sources  (e.g., laboratory, safety,  IRT, 
clinical databases).  
• The conduct of the trial is in compliance with the currently approved 
protocol/amendment(s), with GCP,  and with the applicable regulat ory requirement(s).  
Measures  will be undertaken to protect  the confidentiality  of records  that could  identify  subjects, 
respecting the privacy and confidentiality rules in accordance with applicable regulatory 
requirements.  
 
11.2. Audit  and Inspection 
Authorized representatives of the sponsor, a regulatory authority, an independent ethics committee 
(IEC) or an institutional review board (IRB) may visit the investigator site to perform audits or inspections, including source data verification. The Investigator will allow the sponsor auditor, regulatory authority or ethics committee representative to inspect the drug storage area, study drug stocks, drug accountability records, subject charts and study source documents, and other records relative  to study conduct. The purpose of an audit or inspection is to systematically  and independently 
examine all study -related activities and documents to determine whether these activities were 
conducted, and data were recorded, analyzed, and accurately reported according to the protocol, GCP guidelines of the International Conference on Harmonization, and any applicable regulatory requirements. The investigator should contact [CONTACT_167449] a regulatory agency about an inspection. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  61 of 74  
 12. ETHICS  
12.1. Ethical Considerations 
The study will be conducted in accordance with FDA regulations, ICH E6 Guideline for GCP, the 
Declaration  of Helsinki,  any other applicable regulatory  requirements,  and IRB  or independent ethics 
committee (IEC) requirements.  
 
12.2. Communication  with the Institutional Review Board  or Independent 
Ethics Committee  
This protocol, the Informed Consent Form, the IB, and any information to be given to the subject 
must be submitted  to a properly constituted  IRB/IEC by [CONTACT_464484]/IEC before the study is initiated and before any investigational product is shipped to the Investigator. In addition, any subject  recruitment  materials  must be approved  by [CONTACT_1201]/IEC  before 
the material is used for subject recruitment.  
The investigator is responsible for obtaining reapproval  by [CONTACT_1201]/IEC  annually  or more  frequently 
in accordance with the regulatory requirements and policies and procedures established by [CONTACT_5040]/IEC. Copi[INVESTIGATOR_8268]’s annual report and other required report to the IRB/IEC and copi[INVESTIGATOR_513342]/IEC continuance of approval must  be furnished to FibroGen. A copy of the signed 
form FDA [ADDRESS_664722] also accompany the above approval letter provided to FibroGen. 
Investigators are also responsible for promptly informing the IRB/IEC of any protocol changes or 
amendments,  changes  to the Invest igator’s  Brochure,  and other safety -related  communications from 
FibroGen. Written documentation of IRB approval must be received before the amendment is 
implemented.  
Investigators must also enter  the names  of the staff that are involved in the study on the Delegation  of 
the Authority form and sign the form (including their responsibilities). This form must be updated 
when responsibilities of the staff change. 
 
12.3. Informed  Consent  Form 
No study procedure may be implemented prior to provision of a written Inf ormed Consent Form 
(ICF) from the subject or the subject’s legally authorized representative. Institutional Review 
board/IEC review  and approval are required  for the ICF. The final IRB/IEC  approved ICF  must be 
provided to FibroGen for regulatory purposes. 
If there are any changes to the Sample ICF during  the subjects’ participation in the study, the revised 
ICF must receive the IRB/IEC’s  written  approval before  use and  subjects must be re -consented  to the 
revised version of the ICF. 
Guidance for Clinical Teams: For studies conducted in the [LOCATION_002], each subject must provide 
his or her consent for the use and disclosure of personal health information under the US Health Insurance Portability  and Accountability Act (HIPAA)  regulations by [CONTACT_2960] a HIPAA  Authorization 
Form. The HIPAA Authorization Form may be part of the ICF or may be a separate document. IRB review may or may not be required for the HIPAA Authorization Form according to study site 
policies.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664723]  in writing  that medical  information  be given to 
his/her personal physician. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664724]  all data transcribed  onto the CRFs  and resolved 
queries.  
 
13.2. Data  Collection,  Handling,  and Verification  
All required data will be entered onto CRFs by [CONTACT_1747]. Data will be entered into a 
validated,  clinical  database compliant with 21 Code  of Federal  Regulation (CFR)  Part [ADDRESS_664725]  data will be reviewed  by [CONTACT_166327]/or designee. Data that appear  inconsistent, 
incomplete or inaccurate will be queried for site clarification.  
Medical  history, AEs,  and medications  will be coded  using industry standard  dictionaries  (e.g., 
MedDRA and World Health Organization Drug [WHODrug]) Dictionary. 
The Investigator is responsible for reviewing, verifying, and approving all subject  data,  i.e., CRFs  and 
queries prior to study completion, ensuring that all data is verifiable with source documents. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  64 of 74  
 14. FINANCING  AND  INSURANCE  
Financing and insurance are addressed  in a separate document.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  65 of 74  
 15. PUBLICATION  POLICY  
A detailed  explanation  of the Sponsor’s publication policy is described  in the Clinical Trial 
Agreement.  
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664726] of the study at his or 
her site. The investigator will permit study -related monitoring, audits, IRB/IEC review, and 
regulatory inspection(s), providing direct access to source data/documents. 
 
16.1. Study  Drug  Accountability  
The investigational product (roxadustat) required for completion of this study will be provided by 
[CONTACT_2728]. The recipi[INVESTIGATOR_513343]. Damaged  supplies will be replaced.  
The investigational product, must be maintained  at the study site until Sponsor or its designee verifies 
drug accountability and provides instruction for destruction or the return of the investigational product to Sponsor’s drug distribution depot. 
Accurate records of all study drug received, dispensed, returned, and disposed of by [CONTACT_513363]. 
 
16.2. Disclosure  of Data 
Data records  generated  by [CONTACT_513364], national and local health authorities, Sponsor’s monitors/representatives and collaborators, auditors, and the IRB/IEC for each study site. 
The Investigators should promptly notify the Sponsor and/or designee of any audits scheduled  by [CONTACT_513365][INVESTIGATOR_119257]. 
 
16.3. Retention of Records  
The investigator shall retain records  required  to be maintained under 21 CFR  312.62(c) for a period 
of [ADDRESS_664727] copy is obtainable if required.  No records  will be 
destroyed without the prior written consent of Sponsor. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  67 of 74  
 17. REFERENCES  
Besarab,  A., et al.  "The effects of  normal as compared with  low hematocrit values in patients with 
cardiac disease who are receiving  hemodialysis and epoetin." N Engl J Med 339.9 (1998): 584-90. 
Besarab, A., S. Frinak, and J. Yee. "What is so bad about a hemoglobin level of 12 to 13 g/dL for 
chronic kidney disease  patients  anyway?"  Advances  in Chronic Kidney Disease 16.2 (2009): 131-42. 
Bradbury BD, Danese MD, Gleeson  M, Critchlow  CW "Effect  of Epoetin  alfa dose changes  on 
hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL". Clin J Am Soc Nephrol 4 : 630– 637, 2009 
Bruck, K., et al. “CKD  Prevalence Varies  across  the European General  Population.” JASN 27.7 
(2016): 2135-47. Buchler,  P., et al. "Hypoxia-inducible factor  1 regulates  vascular  endothelial  growth factor  expression 
in human pancreatic cancer." Pancreas 26.1 (2003): 56-64. 
Collins,  A. J., et al. "Trends in anemia treatment  with erythropoietin usage and patient  outcomes." 
American Journal of Kidney Diseases 32.[ADDRESS_664728] 4 (1998): S133-S141. 
Coresh, J., et al. "Prevalence of chronic kidney disease in the United  States."  JAMA  298.17 (2007): 
2038- 47. 
Drueke,  T. B., et al. "Normalization  of hemoglobin level  in patients  with chronic  kidney disease and 
anemia." N Engl J Med 355.20 (2006): 2071-84. 
Epstein  AC, Gleadle JM, McNeill  LA, et al. “C. elegans  EGL -9 and mammalian  homologs define a 
family of dioxygenases that regulate HIF by [CONTACT_270182].” Cell. 2001:107(1):43-54. 
Eschbach, J. W., et al. "Recombinant human erythropoietin in anemic patients with end- stage renal 
disease.  Results  of a phase III multicenter  clinical  trial." Annals of Internal  Medicine 111.12 (1989): 
992-1000.  
Eschbach,  J. W., et al. "Correction  of the anemia of end-stage renal  disease with  recombinant human 
erythropoietin. Results of a combined phase I and II clinical trial." N Engl J Med 316.2 (1987): 73- 
78. 
Eschbach,  J. W.
 , et al. "Treatment  of the anemia of progressive renal  failure  with recombinant human 
erythropoietin." N Engl J Med 321.3 (1989): 158-63. 
Fan, C., et al. "Gene expression and phenotypic characterization  of mouse heart  after chronic constant 
or intermittent hypoxia." Physiol Genomics 22.3 (2005): 292-307. 
Fishbane, S. and A. Besarab.  "Mechanism  of increased  mortality  risk with erythropoietin treatment  to 
higher hemoglobin targets." Clinical Journal of the American Society of Nephrology 2.6 (2007): 
1274- 82. 
Go, A. S., et al. "Chronic kidney disease and the risks  of death,  cardiovascular  events,  and 
hospi[INVESTIGATOR_059]." N Engl J Med 351.13 (2004): 1296-305. 
Gray, M. J., et al. "HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a 
transcriptional complex  that regulates  Src-dependent  hypoxia-induced expression  of VEGF  in 
pancreatic and prostate carcinomas." Oncogene 24.19 (2005): 3110-19. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  68 of 74  
 Greijer,  A. E., et al. "Up-regulation of gene expression by [CONTACT_513366]-inducible factor 1 (HIF-1)." J.Pathol. 206.3 (2005): 291-304. 
Hu, C. J., et al. "Differential roles  of hypoxia-inducible factor  1alpha (HIF -1alpha) and HIF-2alpha in 
hypoxic gene regulation." Mol Cell Biol 23.24 (2003): 9361-74. 
Jungers PY, Robino C, Choukroun G, Nguyen- Khoa  T, Massy  ZA, Jungers P (2002) “Incidence of 
anaemia, and use of epoetin therapy in pre -dialysis patients: a prospective study in 403 patients.” 
Nephrol Dial Transplant 17: (9):1621-[ADDRESS_664729], Critchlow  CW, Fishbane S, Besarab  A, Stehman -Breen  C, Krishnan M, Bradbury BD: 
“Greater epoetin alfa responsiveness is associated with imp roved survival in hemodialysis patients.” 
Clin J Am Soc Nephrol 3 : 1077– 1083, 2008 Langsetmo, I., Nichols, B., Seeley, T., Stephenson, B., Klaus, S., Lin, A., and Liu, D. (2005) 
“FG-2216 Corrects  Anemia  and Improves Iron  Utilization  in a Rat Model of Anemia  of Chronic 
Disease: Comparison to Darbepoetin.” Abstract #F -PO674, J Am Soc Nephrol 16: 481A. 
Ma, J., Ebben, J. Z, Xia, H., Collins, A. J. (1999). Hematocrit Level  and Associated  Mortality  in 
Hemodialysis Patients. J Am Soc Nephrol 10: 610-619. 
NKF  KDOQI.  "KDOQI  Clinical Practice Guideline and Clinical Practice  Recommendations for 
anemia in chronic kidney disease: update of hemoglobin target." American Journal of Kidney Diseases 50.3 (2007): 471-530. 
Peyssonnaux, C., V. Nizet,  and R. S. Johnson. "Role  of the hypoxia inducible factors  HIF in iron 
metabolism." Cell Cycle 7.1 (2008): 28-32. 
Regidor DL, Kopple JD, Kovesdy CP, et al. (2006) Associations between  changes in hemoglobin and 
administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc 
Nephrol. 17: (4):1181-1191 
Scortegagna,  M., et al. "HIF -2a regulates  murine hematopoietic  development in an erythropoietin- 
dependent manner." Blood 105.8 (2005): 3133-40. 
Semenza,  G. L. "Hypoxia-inducible factor  1: master  regulator of O
2 homeostasis." 
Curr.Opin.Genet.Dev. 8.5 (1998): 588-94. 
Semenza GL ( 2000) HIF-1: mediator  of physiological and pathophysiological responses to hypoxia. 
J Appl Physiol 88: (4):1474-1480 
Szczech  LA, Barnhart  HX, Inrig  JK, et al. (2008) Secondary  analysis  of the CHOIR  trial epoetin - 
alpha dose and achieved hemoglobin outcomes. Kidney Int 74: (6):791-798 Singh, A. K., et al. "Correction  of anemia with  Epoetin  alfa in chronic kidney disease."  N Engl J Med 
355.20 (2006): 2085-98. 
Solomon SD, Uno H, Lewis  EF, et al. Erythropoietic response and outcomes in kidney disease and 
type 2 diabetes. N Engl J Med. 2010;363(12):1146-1155. 
Thilly N, Stengel B, Boini S, Villar E, Couchoud C, Frimat L  (2008) Evaluation and determinants of 
underprescription of erythropoiesis stimulating  agents  in pre-dialysis  patients  with  anaemia.  Nephron 
Clin Pract 108: (1):c67-c74 
Tonelli,  M., et  al. "Chronic kidney disease and mortality  risk:  a systematic  review."  J Am  Soc 
Nephrol 17.7 (2006): 2034-47. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  69 of 74  
 Unger, E. F. FDA Perspectives on ESAs for Anemia of Chronic Renal Failure: Hemoglobin Target 
and Dose  Optimization.  9-11-2007. FDA  Department  of Health  and Human  Services.  Joint Meeting 
of the Cardiovascular and renal Drugs Advisory Committee and the Drug Safety and risk Management Advisory Committee. 10-16-2007. 
Unger EF, Thompson AM, Blank  MJ, Temple  R (2010) Erythropoiesis- stimulating  agents  time for a 
reevaluation. N Engl J Med 362: (3):189-192 
U.S. Renal  Data System,  2000 Annual Data Report: Atlas  of End-Stage Renal  Disease in the United 
States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney 
Diseases, Bethesda, MD.  
U.S. Renal  Data System,  2001 Annual D ata Report: Atlas  of End-Stage Renal  Disease in the United 
States,National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.  
U.S. Renal  Data System,  2002 Annual Data Report: Atlas  of End-Stage Renal  Disease in the United 
States,National Institutes of Health, National Institute of Diabetes and Digestive and Kidney 
Diseases, Bethesda, MD.  
U.S. Renal  Data System,  2003 Annual Data Report: Atlas  of End-Stage Renal  Disease in the United 
States, National Ins titutes of Health, National Institute of Diabetes and Digestive and Kidney 
Diseases, Bethesda, MD.  
U.S. Renal  Data System,  2009 Annual Data Report: Atlas  of Chronic Kidney Disease and End-Stage 
Renal Disease in the [LOCATION_002], National Institutes of Health, National Institute of Diabetes and 
Digestive and Kidney Diseases, Bethesda, MD.  
U.S. Renal  Data System,  2011 Annual Data Report: Atlas  of Chronic Kidney Disease and End-Stage 
Renal Disease in the [LOCATION_002], National Institutes of Health, National Institute of Diabetes and 
Digestive and Kidney Diseases, Bethesda, MD.  
U.S. Renal  Data System,  2013 Annual Data Report: Atlas  of Chronic Kidney Disease and End-Stage 
Renal Disease in the [LOCATION_002], National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.  
Wang,  G. L., et al. "Hypoxia-inducible factor  1 is a basic- helix -loop- helix -PAS heterodimer  regulated 
by [CONTACT_2967] O2 tension." Proc Natl Acad Sci [LOCATION_003] 92.12 (1995): 5510-14. 
Warnecke,  C., et al. "Differentiating  the functional role of hypoxia-inducible factor  (HIF) -1alpha and 
HIF-2alpha (EPAS -1) by [CONTACT_167456]: erythropoietin is a HIF- 2alpha target gene in 
Hep3B and Kelly cells." The FASEB Journal 18.12 (2004): 1462-64. 
Winearls,  C. G.
 , et al. "Effect  of human erythropoietin derived  from  recombinant  DNA on the 
anaemia of patients maintained by [CONTACT_167457]." Lancet 2.8517 (1986): 1175-78. 
Xie Y., et al. “Analysis  of the Global Burden of Disease study highlights the global, regional,  and 
national trends of chronic kidney disease epi[INVESTIGATOR_464455] 1990 to 2016.” Kidney Int. 94.3 
(2018):567 -581. 
Yellen,  S. B., et al. "Measuring  fatigue and other anemia -related  symptoms with the Functional 
Assessment of Cancer Therapy (FACT) measurement system." J Pain Symptom.Manage. 13.2 
(1997): 63-74. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  70 of 74  
 Zhang, Y., et al. "Epoetin  requirements  predict  mortality  in hemodialysis patients." American  Journal 
of Kidney Diseases 44.5 (2004): 866-76. 
Zoccali  C, Kramer  A, Jager  KJ. Epi[INVESTIGATOR_270135]: an uncertain  scenario.  Nephrol 
Dial Transplant. 2010;25(6):1731-3. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  71 of 74  
  
 
 
18. APPENDIX  
DocuSign Envelope ID:F8E78CBE -578F -461D -BCDA -949A802CD9B4
Roxadustat Protocol FGCL -4592 -097A2
Confidential Page 72of74
Appendix  1: Roxadustat Dose Adjustment Rules
Current Hblevel:
<10.5 g/dL 10.5 to 11.9 g/dL12.0 to
12.9 g/dL≥13.0 g/dLChange inHbover 
previous 4 weeks:> 1.0 g/dL Nochange ↓ ↓•Hold dosing
•Check Hb and 
resume dosing when 
Hb <12.0 g/dL, at a 
dose reduced by 2 steps-1.0 g/dL to
+1.0 g/dL↑ Nochange ↓
< -1.0 g/dL ↑ ↑ Nochange*
↑:Increase dose by[CONTACT_513346];↓: reduce dose by [CONTACT_80946].
*Continue tohold dose
Notes:
Dose Increases andReductions:
• Dose increases (↑)andreductions (↓)are preset.
• Thedose steps are as follows: 20,40, 50, 70,100, 150, 200, 250, 300, and 400 mg.
If < 20mg/dose is required, dosing frequency should be reduced in a step -wise fashion e.g., TIW to BIW, BIW to QW
• Themaximum dose iscapped at 400mgor3.0mg/kg/dose (whichever is lower). Rounding themg/kg calculated roxadustat 
dose up to 10 mg may be allowed, if no safety concerns.
Roxadustat dose adjustment reviews  should occur every  4 weeks, except if the following criteria are 
met:
•Rate of Hb rise > 2 g/dL within  4 weeks:  reduce dose by 1 dose step
•Hblevel  > 13g/dL: hold dose, until Hb  drops to  < 12g/dL, resume dosing at 2 dose steps 
lower
Dose adjustments  or temporary  dose holds for excessive rate ofHbriseorHb above 13 g/dL can 
occur at any time during the Treatment Period. 
Prescribed  dose must not exceed the maximum allowable dose of 3.0 mg/kg/dose or 400 mgper dose, 
whichever islowe r; rounding the mg/kg calculated  roxadustat dose up to 10mgmay be allowed, if no 
safety  concerns. For  dose adjustment purposes, estimated dry-weight at enrollment should be used for 
the entire duration of the treatment period. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -4592 -097 A2 
Confidential  Page  73 of 74  
  
Appendix  2: Liver Function  Monitoring  
The guidelines described in this section are intended to enable early detection and action following 
abnormal liver function test (LFT) results.  Any patient enrolled in a clinical study with active drug 
therapy and reveals an increase of serum aminotransferases (AT) to > 3 × upper limit o f normal 
(ULN), or bilirubin > 2 × ULN, should undergo detailed testing (including at least alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP], and total bilirubin [TBL]) for further evaluation and follow-up. Alert s will be generated by [CONTACT_513367], study monitor and study team. Testing should be repeated within 48-[ADDRESS_664730] any symptoms suggestive of hepatobiliary 
dysfunction.  
Definition  of Liver Abnormalities  
Confirmed  abnormalities  should be characterized  as follows:  
 
 ALT  or AST   Total  Bilirubin  
Moderate  > 3× ULN  Or > 2× ULN  
Severe  > 3× ULN  And > 2× ULN  
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal. 
Hy’s  Law:  Drug -induced jaundice  caused  by [CONTACT_513368],  without  a significant obstructive  component,  has a 
high rate of bad outcomes, from 10% to 50% mortality (or tr ansplant). The two “requirements” for Hy’s Law are:  
1) Evidence  that a drug can cause  hepatocellular -type injury,  generally  shown by [CONTACT_513369] 3 times  the upper  limit of normal  (“2 × ULN elevations  are too common in treated and  untreated Patients  to 
be discriminating”).  2) Cases of increased bilirubin (at least  2 × ULN) with concurrent transaminase elevations at least 
3 × ULN and no evidence of intra - or extrahepatic bilirubin obstruction (elevated alkaline phosphatas e) or Gilbert’s 
syndrome: Temple, R (2006) Hy's law: predicting serious hepatotoxicity. Pharmacoepi[INVESTIGATOR_9697] 15: (4):[ADDRESS_664731]  severe hepatic  abnormalities  for any of the 
following:  
• ALT  or AST  > 8× ULN  
• ALT  or AST  > 5× ULN  for more  than 2 weeks  
• ALT  or AST  > 3× ULN and  international normalized  ratio (INR)  > 1.5 (if INR  testing  is 
applicable/evaluated).  
• ALT  or AST  > 3× ULN with  the appearance of fatigue, nausea,  vomiting, right upper 
quadrant pain or tenderness, fever, rash and/or eosinophilia (> 5%). 
The investigator may determine  that abnormal liver function results,  other than as described  above, 
may qualify as moderate or severe abnormalities and require additional monitoring and follow-up. 
DocuSign  Envelope  ID: F8E78CBE -578F -461D -BCDA -949A802CD9B4  
Roxadustat  Protocol  FGCL -[ADDRESS_664732], TBL and ALP 
In addition, evaluate the patient  for potential causes,  which  may include the following:  
• Detailed  history of symptoms and prior or concurrent  diseases  
• Concomitant drug use, including nonprescription medications,  herbal  and dietary 
supplements, alcohol or recreational drug use, or special diets 
• Exposure to environmental chemical  agents  
• Rule out acute  viral hepatitis  Types A,B,C,D,E; autoimmune or alcoholic hepatitis; 
nonalcoholic steatohepatitis; hypoxic/ischemic hepatopathy; biliary tract disease  
• Obtain  additional tests as appropriate: e.g., INR,  gamma  glutamyltransferase  (GGT) or 
direct bilirubin; ultrasound or other imaging to assess biliary tract disease 
• Consider gastroenterology or hepatology consultations  
In general,  in the absence  of an explanation  for increased  LFTs,  such as viral hepatitis,  preexisting or 
acute liver disease or exposure to other agents associated with liver injury, the study drug should be 
discontinued.  
Discontinuation of treatment  should be considered if: 
• ALT  or AST  > 8 × ULN  
• ALT  or AST  > 5 × ULN for more  than 2 weeks  
• ALT  or AST  > 3 × ULN and  TBL > 2 × ULN  or INR  > 1.5) (If INR  testing  is 
applicable/evaluated)  
• ALT  or AST  > 3 × ULN with the appearance of fatigue, nausea,  vomiting, right upper 
quadrant pain or tenderness, fever, rash and/or eosinophilia (> 5%) 
Once LF Ts  return  to normal, and depending on whether  there is an explanation for the LFT 
elevations, study drug dosing may resume, after discussion with the Medical Monitor 
See also: FDA  Guidance  for Industry,  titled: “Drug -Induced Liver Injury:  Premarketing 
Clinical Evaluations”, issued July 2009 